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Antimicrobial resistance is one of the biggest threats to public health globally. Modifications to 
ciprofloxacin, a commercially available fluoroquinolone antibiotic, could overcome increasing 
antimicrobial resistance and increase its antimicrobial activity.  
Ciprofloxacin contains several potential donor atoms, which can be used to coordinate to a 
metal ion. Coordination of ciprofloxacin to bioavailable metal ions such as iron(III) could 
promote bacterial uptake of the metallo-ciprofloxacin complex, making it a more effective 
antimicrobial agent over ciprofloxacin. The coordination of ciprofloxacin to metal ions with 
antimicrobial properties such as bismuth(III) could also further enhance the antimicrobial 
properties. Presented are two novel iron(III)-ciprofloxacin complexes, a novel zinc(II)-
ciprofloxacin complex and a bismuth(III)-ciprofloxacin complex. The metallo-ciprofloxacin 
complexes presented have been characterised using a variety of techniques, including X-ray 
crystallography, X-ray fluorescence (XRF), fourier-transform infrared spectroscopy (FTIR), 
elemental analysis, solid state nuclear magnetic resonance (ssNMR) and melting point. 
Another modification that can be made to the structure of ciprofloxacin is to design and 
synthesise a linked dimers.  A dimeric compound could bridge across the binding sites of the 
intracellular target enzyme, DNA gyrase. Previously reported fluoroquinolone dimers have been 
found to possess enhanced antimicrobial properties as well as anti-tumour properties. 
Presented are two ciprofloxacin dimers, the first featuring an ethylenediaminetetraacetic acid 
(EDTA) linker and the second a diethylenetriamine pentaacetate (DTPA) linker. The EDTA and 
DTPA linkers have also been suggested to have antimicrobial properties due to their metal-
chelating properties and therefore could further enhance the effectiveness of the ciprofloxacin 
dimers presented. The linked ciprofloxacin ligands presented have been characterised using 
nuclear magnetic resonance (NMR), High-performance liquid chromatography (HPLC), FTIR, 
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1.  Introduction  
 
1.1 History of fluoroquinolones 
 
Antimicrobial resistance is one of the biggest threats to public health globally1. Fluoroquinolones 
are a group of molecules with a pharmacophore shown in figure 1. They have broad spectrum 
antimicrobial properties and are commercially available as oral antibiotics, often used to treat 
infections such as urinary tract infections, gastrointestinal infections, respiratory tract 
infections, sexually transmitted diseases and skin infections 2,3.  
 
Figure 1: pharmacophore of fluoroquinolones. 
The first fluoroquinolones developed were second generation quinolones. The first clinically-
available fluoroquinolone was norfloxacin (1), patented in 1977 4. The success of this drug saw 
the development of several more fluoroquinolone antibiotics within the next three years, many 
of which are still commonly used to treat infections today. These include: pefloxacin (2), 
enoxacin (3), fleroxacin (4), ciprofloxacin (5) and ofloxacin (6)5 (figure 2). Second generation 
quinolones can be subdivided into Class I and Class II fluoroquinolones, with Class II 
fluoroquinolones exhibiting higher serum, tissue, and intracellular drug concentrations 
compared with Class I second generation quinolones6,7. Of the second generation quinolones 
listed (figure 2) ciprofloxacin (5) and ofloxacin (6) are Class II, whereas the (1)-(4) are Class I 
second generation quinolones. When these fluoroquinolones were first brought onto the 
market, there was virtually zero resistance, however for many infections, fluoroquinolones are 




Figure 2: structures of fluoroquinolones marketed in the early 1980s norfloxacin (1), pefloxacin 
(2), enoxacin (3), fleroxacin (4), ciprofloxacin (5) and ofloxacin (6). 
In 1985 third generation quinolones were being developed. Third generation quinolones are also 
fluoroquinolones but unlike the second-generation quinolones, they are active against 
Streptococci bacteria. This paved the way for fourth-generation quinolones; fluoroquinolones 
similar to the third generation quinolones but with increased antimicrobial activity in Gram-





Figure 3: timeline showing the development of quinolone generations with examples and their 
structures for each.  
 
1.2 Fluoroquinolones: mechanism of action and structure-activity relationship 
 
Fluoroquinolones enter bacterial cells mainly via porins and passive diffusion and interact with 
DNA gyrase, the intracellular drug target 9. DNA gyrase is an enzyme involved in the supercoiling 
of DNA in bacterial cells 10.  
A cyclopropyl group in the R1 position (figure 1) has been found to be the optimum substituent 
due to its favourable steric, spatial and through-space interactions. This makes ciprofloxacin (5) 
one of the most potent fluoroquinolone antibiotics available. In position 2, a hydrogen atom is 
the optimal substituent, but antimicrobial activity has been demonstrated with small rings 
connecting to C1 or C3. The ketone/ carboxylic acid groups in positions 3 and 4 respectively are 
essential for binding to DNA gyrase and bacterial transport and therefore modifications should 
not be made here. It has been suggested that adding a nitrogen atom to the ring to replace C5 
could increase potency against Gram-positive bacteria, this is shown through the increase in 
antibacterial effectiveness from pefloxacin (2) to enoxacin (3). The fluorine substituent in 
position 6 is essential to the pharmacophore of fluoroquinolones and has been shown to 
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significantly increase effectiveness of the antimicrobial properties of quinolones. In position 7 
five and six membered nitrogen containing rings have been shown to be most effective, such as 
the diazene ring in norfloxacin (1), enoxacin (3) and ciprofloxacin (5) 11,12.    
 
Figure 4: fluoroquinolone pharmacophore with labelled structure activity relationship and 




Fluoroquinolones contain several donor atoms which could potentially coordinate to metal ions. 
The pharmacophore of fluoroquinolones (figure 1) contains three oxygen atoms, which could 
coordinate to a metal ion: two in the carboxylate substituent on C3 (when deprotonated) and 
one in the ketone group on C4. “ The lone pair of electrons on the nitrogen atom in position 1 of 
the pharmacophore (figure 1) are sterically less available due to the R1 substituent, meaning it 
is not a good donor atom. Donor atoms can be introduced into fluoroquinolone structures 
through the R1 and R2 substituents. A common R2 substituent is a piperazine ring, as seen in 
norfloxacin (1), pefloxacin (2), enoxacin (3), fleroxacin (4), ciprofloxacin (5) and ofloxacin (6) 
(figure 2). A piperazine ring introduces two additional nitrogen atoms, capable of coordinating 
to a metal ion.  
Coordination of fluoroquinolones to a metal most often occurs through the ketone and 
carboxylic acid groups in positions 3 and 413. A coordinative bond is formed from the oxygen 
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from the OH group in the carboxylate substituent (formed by the loss of a proton) and a 
coordinative bond through the ketone oxygen (figure 5).  
 
Figure 5: a general reaction scheme of fluoroquinolone with a metal M(III) cation to form a 
metallo-fluoroquinolone in hydrochloric acid. The scheme shows how fluoroquinolones can 
coordinate to metals: through the carboxylate/ ketone groups in positions 3 and 4 respectively. 
It has been suggested that zinc(II) from biomolecules coordinates to the fluoroquinolone 
levofloxacin via the more rarely seen coordination through nitrogen atoms in the R2 substituent, 
which is a 1-methylpiperazine group in levofloxacin (figure 6) 14.  This form of coordination 













Figure 6 : structure of complex formed by zinc(II) ions from biomolecules and levofloxacin in 
blood plasma exhibiting coordination via nitrogen atoms in the 1-methylpiperazine group in the 
R2 position 14. 
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Additionally, there are examples of coordination of fluoroquinolones such as norfloxacin (1) to 
iron(III) and cobalt(II) through the two carboxylate oxygen atoms in the β-ketone carboxylate 
group. The novel iron(III) and cobalt(II) norfloxacin complexes were synthesised by F. Gao et al. 
in 1995, the proposed structure from UV-vis, NMR and elemental analysis characterisation is 
shown in figure 7 16, 17. 
 
Figure 7: general structure of coordination of norfloxacin to a metal cation (2+) through the two 
oxygen donor atoms in the β-ketone carboxylate group 16, 17. 
 
1.3.1 Choice of bacteria to assess antimicrobial effectiveness   
 
Across a range of metal and fluoroquinolone combinations, there is a large variation in 
effectiveness in different strains of bacteria. Whilst fluoroquinolones are broad spectrum 
antibiotics, metallo-fluoroquinolones could have more effective applications if used to treat 
specific bacterial strains. Metallo-fluoroquinolone complexes have potential to be effective 
against bacterial strains that are resistant to the parent fluoroquinolone drugs. Complexes of 
1:3 bismuth(III)-norfloxacin and 1:4 bismuth(III)-norfloxacin were found to have lower minimum 
inhibitory concentration (MIC) values versus their parent fluoroquinolone over a range of 
clinically-relevant bacteria. Most notably these complexes were effective against strains of 
Helicobacter pylori which are resistant to fluoroquinolones, showing a sixteen fold decrease in 




Table 1:  MIC values of [Bi(norfloxacin)3(H2O)2] and norfloxacin against fluoroquinolone resistant 
strains of H. pylori. 
 MIC (mg L-1) for strain No. of H. pylori 
 2304 2287 2662 
[Bi(norfloxacin)3(H2O)2] 1.0 1.0 1.0 
norfloxacin 16.0 16.0 16.0 
 
Similarly, in a 1:1 copper(II)-ciprofloxacin complex, the antibacterial activity was found to be the 
same as ciprofloxacin administered on its own across a range of clinically-relevant bacteria apart 
from Pseudomonas aeruginosa and Salmonella typhimurium. In P.aeruginosa and 
S.typhimurium strains the copper(II)-ciprofloxacin complex increased the inhibition zone by 10 
mm and 7 mm respectively21. The potential for metallo-fluoroquinolones to overcome 
fluoroquinolone resistance in bacteria demonstrates the importance of testing complexes on a 
wide range of clinically-relevant bacteria and the significant potential metallo-fluoroquinolones 
demonstrate against rising antimicrobial resistance.  
Conversely, a study investigated the antimicrobial properties of tris(quinolono)metal(III) 
complexes of gallium(III) and iron(III) with each of the following nine fluoroquinolones in a 1:3 
metal(III)-to-fluoroquinolone ratio: nalidixic acid, norfloxacin (1), fleroxacin (4), oxolinic acid, 
enoxacin (3), levofloxacin, pipermidic acid, ciprofloxacin (5) and lomefloxacin. The single disk 
method against pathogens associated with nosocomial diseases was used to evaluate the 
antimicrobial properties of these complexes compared to the equivalent concentration of 
fluoroquinolone if it were not coordinated to a metal ion, by measuring the inhibition zone sizes. 
The study concluded that the each one of the tris(quinolono)metal(III) complexes tested against 
each strain of bacteria showed no change in the antimicrobial properties when compared to the 
parent fluoroquinolone, including in Klebsiella pneumoniae, which had developed a resistance 
to nalidixic acid and subsequently was also resistant to [Ga(nalidixic acid)3] and [Fe(nalidixic 
acid)3]22.  
1.3.2 Choice of fluoroquinolone 
 
The type of fluoroquinolone influences the effectiveness of the metal-fluoroquinolone 
complexes. In a 1:1 copper(II)-ciprofloxacin complex, the MIC was found to be lower than 
ciprofloxacin in certain bacteria18 , however in a 1:1 copper(II)-lomefloxacin complex there was 
no change in the MIC across a range of bacteria in comparison to lomefloxacin alone 23, 24. 
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The antimicrobial properties of a range of [bismuth(III)-(fluoroquinolone)3(H2O)2] complexes 
found that for each strain of bacteria was most susceptible to a different complex. All of the 
[bismuth(III)-(fluoroquinolone)3(H2O)2] complexes synthesised were found to have enhanced 
antimicrobial properties over the parent fluoroquinolone, across a range of clinically-relevant 
bacteria. The bismuth(III)-ciprofloxacin complex was found to be most potent against E. coli with 
MIC of 0.05 mg L–1 whereas bismuth(III)-ofloxacin complex was the most potent against S. aureus 
(MIC: 0.125 mg L–1) and B. pumilus (MIC: 0.045 mg L–1) and bismuth(III)-sparfloxacin complex 
against S.epidermidis (MIC: 0.125 mg L–1), suggesting that the choice of parent fluoroquinolone 
will alter the effectiveness of the metallo-fluoroquinolone complex against different strains of 
bacteria18.  
In [iron(III)(fluoroquinolone)3] complexes whereby the fluoroquinolones included: nalidixic acid, 
norfloxacin (1), fleroxacin (4), oxolinic acid, enoxacin (3), levofloxacin, pipermidic acid, 
ciprofloxacin (5) and lomefloxacin, there was a positive correlation with the antibacterial 
properties of the parent fluoroquinolone and the antibacterial properties of the iron(III)-
fluoroquinolone complex suggesting the more potent the parent fluoroquinolone is, the more 
effective the metal complex will be22. 
The choice of fluoroquinolone will also influence the stability of the complex. There is variation 
in stability constants (table 2) within a range of metal-fluoroquinolone combinations, which 
reflect the strength of the interaction between the fluoroquinolone ligand and the metal cation. 
Stability constants were calculated using capillary zone electrophoresis experiments at pH 3.25 
for the iron(III) and aluminium(III) complexes and at 8.02 for the magnesium(II) complexes, as 
these were determined to be the optimum pH values for the respective metal complexes. All  
experiments were undertaken at 298 K and measured with a 30 kV separation potential. This 
study found that for Al(III) and Fe(III), coordination to norfloxacin appears to be the most 
favourable and lomefloxacin the least favourable, with a stability constant less than a third of 
that of norfloxacin in Al(III) and half in Fe(III). There is similarly a large range of stability constants 
when different fluoroquinolones are coordinated to Mg(II) however, a different pattern is 
observed with levofloxacin forming the most stable complex, suggesting that the oxidation state 




Table 2: The stability constants (K) for a range of fluoroquinolone-metal ion complexes 
calculated using capillary zone electrophoresis at 298 K with a 30 kV separation potential and  
pH 3.25 for Fe(III) and Al(III) complexes, 8.02 for the Mg(II) complexes 25.  
Fluoroquinolone K ± ∆K (L mmol-1) 
Fe(III) Al(III) Mg(II) 
ciprofloxacin  14.117 ± 0.223 14.184 ± 0.218 2.744 ± 0.074 
norfloxacin  20.113 ± 0.181 34.091 ± 0.249 3.545 ± 0.038 
ofloxacin 14.659 ± 0.225 17.901 ± 0.202 4.488 ±0.021 
levofloxacin 9.146 ± 0.199 24.275 ± 0.168 5.578 ± 0.019 
lomefloxacin 8.910 ± 0.206 10.653 ± 0.194 3.674 ± 0.029 
enrofloxacin  15.491 ± 0.149 10.564 ± 0.189 3.385 ± 0.200 
sparfloxacin 17.781 ± 0.139 12.319 ± 0.192 1.360 ± 0.064 
 
1.3.4 Choice of metal  
 
The properties of the metal ion used to coordinate to a fluoroquinolone are also significant. In 
metallo-fluoroquinolone complexes, the fluoroquinolone coordinates through donor atoms and 
the metal ion accepts electron density. Simplistically, this describes a reaction between a Lewis 
acid and a Lewis base, whereby the fluoroquinolone is the Lewis base and the metal ion is the 
Lewis acid. The softness (or hardness) of a species is classified by its size, charge or oxidation 
state, electronic structure, and the other attached groups and is often consistent with the 
electronegativity of a species26. Soft species are often larger and more polarisable, whereas 
harder species are smaller and highly charged. The donor atoms we most commonly see 
coordinated to metal ions in metallo-fluoroquinolone complexes are the deprotonated oxygen 
from the carboxylate group at C3 (RCO2-) and the oxygen from the ketone on C4 (R2O) (figure 1). 
Both donor atoms are Lewis basic and are classified as hard bases 26. Hard Soft Acid Base theory 
suggests that hard Lewis acids prefer to bond to hard Lewis bases and soft Lewis acids prefer to 
bond to soft Lewis bases, meaning that the hard basic oxygen atoms in fluoroquinolones have a 






Table 3: Pearson classification of a selection of Lewis acid metal ions, categorised as soft, 
intermediate and hard26.  
Soft Intermediate Hard 
Cu(I), Ag(I), Au(I) Fe(II), Co(II), Ni(II), Zn(II), Cu(II) Mg(II), Al(III), Se(III), Ga(III), 
Co(III), Fe(III) 
 
Hard Soft Acid Base theory suggests why metallo-fluoroquinolone complexes are most often 
seen with hard metal ions such as metal(III) ions: iron(III), gallium(III), bismuth(III) and some 
complexes with intermediate metal(II) ions: copper(II) and zinc(II). It follows that studies of 
formation constants suggest that that coordination of ciprofloxacin (5) to metal ions increases 
according to the order: Ca(II)< Mg(II)< Zn(II)∼Fe(II)< Cu(II)< Al(III)∼ Fe(III) 27. 
The stability constants of metallo-fluoroquinolone complexes vary depending on the metal. 
Stability constants of various 1:1 metal(II)-nalidixic acid complexes were calculated from 
fluorescence data28, 29(table 4) for the reaction:  





Where: 𝑀  is the metal(II) ion  
            𝐴   is nalidixic acid  
           𝑀𝐴  is the metal(II)-nalidixic acid complex  
           𝐾   is the first equilibrium stability constant for the reaction  
Even though all four metal(II) ions are classed as intermediate Lewis acids (table 3), there is a 
significant variation in the stability constants of the 1:1 complexes they form with nalidixic acid, 
suggesting certain metals are more suitable for complexation with fluoroquinolones than 
others. Fluorescence spectroscopy experiments suggest that metal(II) affinity for nalidixic acid 





Table 4: stability constants from fluorescence of 1:1 metal(II)-Nalidixic acid complexes from two 
different studies 28, 29.  
Metal(II) ion Log K1 28 Log K1 29 
Fe(II) 3.86 ± 0.03 - 
Co(II) 4.22 ± 0.02 4.4 
Cu(II) 5.38 ± 0.03 5.5 
Zn(II) 3.30 ± 0.03 3.8 
 
This pattern conforms with the observations of the Irving-Williams series, whereby the trend in 
stability for divalent first row transition metals in high-spin octahedral complexes for the 
substitution of water for another ligand is as follows: Mn(II)<Fe(II)<Co(II)<Ni(II)<Cu(II)>Zn(II) 30.  
A careful consideration of side reactions and how the complex will react in a biological system 
is critical for any drug. It is important to use a metal that will be transported in vivo but also will 
limit side reactions, such as electron transfer reactions with biomolecules. Cobalt(II)-enoxacin 
(3) complexes have been shown to have an increased MIC across a range of clinically relevant 
bacteria in comparison to enoxacin on its own. This suggests that the chelation to the cobalt 
metal ion reduces the antimicrobial effectiveness of fluoroquinolones and therefore is not 
suitable for use in metallo-fluoroquinolone drugs 31, 32. The reason for this could be due to 
cobalt’s interaction with other biological molecules. A study found that there is a mechanism in 
which cobalt(II) ions chelated to ciprofloxacin ligands interact with adenosine triphosphate (ATP) 
and form an intermediate. This facilitates a reaction between ciprofloxacin and ATP 33. This 
mimics competitive inhibition with other biological molecules and could explain why the cobalt-
enoxacin complex has an increased MIC. Whilst metals that are biologically relevant may have 
transportation benefits for the metallo-fluoroquinolone complexes, caution should be paid to 





1.3.5 Type of bonding  
 
The positive metal ion is surrounded by the donor atoms from the fluoroquinolone ligands, 
creating an electrostatic attraction, thus coordinating the fluoroquinolone to the metal ion. As 
the number of fluoroquinolone ligands increases from one to three, the metallo-
fluoroquinolone complexes tend towards an octahedral geometry, meaning that there is large 
repulsion between the metal ion d electrons and the p electron orbitals of the oxygen donor 
atoms from the carboxylate group in the C3 position of fluoroquinolones. This means that there 
is very weak orbital overlap, making the fluoroquinolone ligands labile. If the fluoroquinolone 
ligands are labile, this could influence the mechanism of action of the drug complex in vivo; 
under biological conditions, the complex could dissociate, altering the metal-to-ligand ratio.  
Titrations and 1H-NMR experiments suggest that the coordination ability of fluoroquinolones 
varies between species. Coordination to Al(III) ions increases as follows: levofloxacin > 
ciprofloxacin > lomefloxacin34 (figure 8). The differences in strength of coordination between 
these three complexes could be due to the different substituents at C8. Ciprofloxacin has no 
substituent whereas lomefloxacin has an electron withdrawing group and levofloxacin has an 
electron donating group in the C8 position. The electron donating  ability of the C8 substituent of 
levofloxacin stabilises the complex formed with the Al(III) ion, whereas the electron withdrawing 
fluorine in the C8 position of lomefloxacin destabilises the complex formed with Al(III).  
 
Figure 8: structures of ciprofloxacin (top left), lomefloxacin (top right) and levofloxacin (bottom) 
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The change in enthalpy on reaction of ciprofloxacin (5) and Ca(II) and Mg(II) ions has been 
calculated from experiments on the temperature dependence of the stability constants for these 
reactions (table 5)35. The enthalpy change on the coordination of one ciprofloxacin ligand (∆H1) 
and of a second ciprofloxacin ligand to the metal(II)-ciprofloxacin complex (∆H2) are both 
negative, suggesting the formation of a bond between the metal(II) ion and the ciprofloxacin 
ligands. However, the magnitude of the enthalpy changes are very small relative to other bond 
enthalpies, with ∆H1 being of a similar strength to a weak O-O bond for both metal(II) ions. 
Furthermore, the ∆H2 values for both metal(II) complexes are even weaker. This is further 
evidence that fluoroquinolone ligands are coordinated to metal ions in metallo-fluoroquinolone 
complexes by relatively weak electrostatic attraction. This data also suggests that the second 
coordinated ciprofloxacin is more weakly coordinated to the metal(II) ion than the first 
ciprofloxacin ligand, which will be due to the weaker electrostatic attraction between the 
negatively charged oxygen donor atom on the carboxylate in the C3 position of ciprofloxacin and 
the [metal(II)(ciprofloxacin]+ complex versus the same ligand interacting with a metal(II) ion. It 
is also important to note, that as explained in previous sections, metal(II) ions are normally of 
intermediate “hardness” (table 3) and therefore not as ideally suited for coordination with a 
hard oxygen donor atom from the carboxylate ion in ciprofloxacin as a hard metal ion such as a 
metal(III) ion.    
Table 5: enthalpy (kJ mol-1) of reactions between Ca(II)/ Mg(II) metal ions with ciprofloxacin (5) 
calculated from the temperature dependence of the stability constants of the reactions. ∆H1 
represents the enthalpy change on the coordination of a single ciprofloxacin ligand and ∆H2 
represents the enthalpy change on the coordination of a second ciprofloxacin ligand to the 
metal(II)-ciprofloxacin complex35.  
 Enthalpy (kJ mol-1) 
∆H1 ∆H2 
Ca(II) -157.86 -35.23 
Mg(II) -163.00 -29.02 
 
Whilst bismuth(III)-fluoroquinolone complexes have been shown to be more effective against 
bacteria than the parent fluoroquinolone 18, 19 , an ionic complex of bismuth and ciprofloxacin 
(5) showed no change to the MIC, and therefore no change in effectiveness against the MIC of 
ciprofloxacin over a range of clinically relevant bacteria 36. The difference in bonding of 
fluoroquinolones to the bismuth(III) ion is determined by X-ray crystallography and IR analysis. 
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X-ray crystallography structures show Bi(III)Cl6 not coordinated to the fluoroquinolone in the 
ionic complex 18, 19 and IR data showed the absence of a peak at 1725 cm–1 (C=O in the 
carboxylate) and emergence of additional peaks at about 1520 and 1455 cm–1 due to 
symmetrical and asymmetrical carboxylate stretching vibrations in complexes where the 
bismuth(III) ion is coordinated to the fluoroquinolone36. Furthermore, when bismuth(III) and 
fluoroquinolones were tested uncoordinated as an admixture, this also had no effect on the MIC 
value, compared to the fluoroquinolone on its own 37, 38, 39. Therefore, the complexation of the 
metal and the fluoroquinolone is essential to the mechanism of action.    
 
1.3.6 Metal-to-ligand ratio 
 
The metal-to-ligand ratio affects the transportation of the drug through biological systems and 
may also affect the drugs ability to bind to the target enzyme. 1:2 and 1:1 copper(II)-
ciprofloxacin complexes have been synthesised, exhibiting different antimicrobial properties. 
The 1:1 copper(II)-ciprofloxacin complex showed exactly the same MICs as ciprofloxacin on its 
own over a range of clinically relevant bacteria in all but three cases: Enterococcus, 
Staphylococcus aureus and Bacillus pumilus, where there was a 50% reduction in the MIC 31, 18. 
The 1:1 copper(II)-ciprofloxacin complex had the same MIC values as the 1:2 complex in 
antimicrobial tests on these three bacteria. However, the MIC of the 1:2 complex was higher 
than ciprofloxacin on its own against five of the other bacterial strains tested 14, 31. This suggests 
that not only does chelation to copper ions decrease the antimicrobial effectiveness of 
fluoroquinolones against some bacteria (further to the studies discussed on this section), but 
that there is influence of the metal-to-fluoroquinolone ratio in the antimicrobial activity of 
metallo-fluoroquinolone drugs.  
Two separate studies investigated bismuth(III)-norfloxacin complexes with two water ligands. 
One study synthesised a 1:3 bismuth(III)-norfloxacin complex; Bi(norfloxacin)3(H2O)2 18, and the 
other a 1:4 bismuth(III)-norfloxacin complex; Bi(norfloxacin)4(H2O)2 19(figure 9). Both studies 
measured the minimum inhibitory concentrations of these complexes against a range of 
clinically-relevant bacteria, they both tested the MIC against Escherichia coli, Bacillus pumilis, 
Staphylococcus aureus and Staphylococcus epidermidis. Both complexes were found to have 
more effective antimicrobial properties than norfloxacin against the bacterial strains tested 
(other than the 1:3 complex against E. coli where the MIC was the same as norfloxacin). Each 
study found different MIC concentrations for norfloxacin for the same strains of bacteria, this 
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may be due to slightly different stains/ methods being used, therefore to compare the reported 
antimicrobial effectiveness we can use the percentage reduction in MIC of each complex, 
relative to the MIC of norfloxacin in the same bacteria from the investigation into each complex 
respectively. There is a greater percentage reduction in MIC across three out of the four bacterial 
strains in the 1:4 bismuth(III)-norfloxacin complex compared to the 1:3 bismuth(III)-norfloxacin 
complex. However the 1:3 bismuth(III)-norfloxacin complex has a greater percentage reduction 
(80%) in MIC compared to norfloxacin in B. pumilis than the 1:4 bismuth(III)-norfloxacin complex 
(50%) (table 6).   
 
Figure 9: reported structures of Bi(III)(norfloxacin)3(H2O)2 18 (7) and Bi(III)(norfloxacin)4(H2O)2 
16(8). 
 
Table 6: the percentage reduction in minimum inhibitory concentration (MIC) for 
[Bi(norfloxacin)3(H2O)2]18 and [Bi(norfloxacin)4(H2O)2] 19 against Escherichia coli, Bacillus pumilis, 
Staphylococcus aureus and Staphylococcus epidermidis.  
 
Bismuth(III):norfloxacin 
Reduction in MIC compared to norfloxacin for different bacteria 
(%) 
E. coli B. pumilis S. aureus S. epidermidis 
1:3 0 80 10 17 




The stepwise equilibrium stability constants K1 and K2 have been calculated via fluorescence 
spectroscopy 28(table 7) for a range of metal(II) ions and their successive binding of nalidixic acid, 
according to the equations below:  
𝑀 + 𝐴 ⇌ 𝑀𝐴  
𝑀𝐴 + 𝐴 ⇌  𝑀𝐴  
Where: 𝑀  is the metal(II) ion  
          𝐴   is nalidixic acid  
          𝑀𝐴  / 𝑀𝐴   are the metal(II)-nalidixic acid complex  









Table 7: values for stability constants K1 and K2 for the above reactions for a range of metal(II) 
ions in the complexation of 1:1 metal(II)-nalidixic acid and 1:2 metal(II)-nalidixic acid according 
to the above reactions at pH 6.428.  
Metal(II) ion Log K1 Log K2 
Fe(II) 3.86 ± 0.03 3.0 ± 0.1 
Co(II) 4.22 ± 0.02 3.0 ± 0.1 
Cu(II) 5.38 ± 0.03 4.1 ± 0.1 
Zn(II) 3.30 ± 0.03 2.3 ± 0.1 
 
The stability constants at pH 6.4 are lower for all the 1:2 metal(II)-nalidixic (K2) acid than the 1:1 





1.3.7 Summary and conclusions 
 
There are five key considerations when designing and synthesising metallo-fluoroquinolones. 
Firstly, it is important to consider the choice and combination of fluoroquinolone and metal, as 
well as the metal-to-fluoroquinolone ratio. It is essential that the metal and fluoroquinolone are 
strongly bound, however coordination of metal ions and fluoroquinolone ligands is often via 
weak electrostatic interactions and hence kinetically labile. Finally, once a suitable metallo-
fluoroquinolone has been synthesised, it should be tested on a wide range of clinically relevant 
bacteria, including bacterial strains resistant to fluoroquinolone drugs, in order to fully evaluate 
its effectiveness and potential as an antibiotic.  
Table 8: summary of findings reported in the literature on different combinations of metals, 
fluoroquinolones (FQ) and  metal-fluoroquinolone ratios.  
Metal (M) Fluoroquinolone (F) M:F Effectiveness 
Bismuth(III) Ciprofloxacin (5) 1:3 Lower MIC than uncoordinated FQ, even 
in FQ resistant bacteria, H.pylori18,19 
Bismuth(III) Norfloxacin (1) 1:4 
Copper(II) Ciprofloxacin (5) 1:1 Higher MIC than uncoordinated FQ18 
Copper(II) Ciprofloxacin (5) 1:2 Lower MIC than uncoordinated FQ in 
certain bacteria, otherwise no change31 
Copper(II) Lomefloxacin 1:1 Same MIC as uncoordinated FQ23 
Cobalt(III) Enoxacin (3) 1:1 Higher MIC than uncoordinated FQ31 
Zinc(II) Ciprofloxacin  1:2 Lower MIC than uncoordinated FQ 40, 41, 42 
 
1.4 Complexes of fluoroquinolone dimers  
 
Multi-component antibiotic systems are a promising approach in the development of new 
antibiotics 43. Dimeric compounds have been shown to demonstrate unique properties over 
their parent monomers in some bioactive compounds in which the biological target contains at 
least two binding sites. An example of this is the antimalarial drug, bisquinoline, which was found 
to be significantly more potent than the original chloroquinoline monomer 44. In theory, dimer-
based drugs are able to bridge across a target molecule’s binding sites 45, a potential solution to 
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overcome the unfavourable entropy cost of two monomers binding to a target molecule46, 
similar to the chelation effect. Furthermore, as the target protein is a dimer, when one side of 
the dimer is bound, the other side will be held in proximity to the other target binding site, 
enhancing binding kinetics. The antimicrobial and anti-tumour properties of complexes of 
dimeric fluoroquinolones have been investigated.  
1.4.1 DNA gyrase: fluoroquinolone drug target 
 
In Gram-negative bacteria, DNA gyrase is the primary intracellular target for fluoroquinolones. 
DNA gyrase is a type II topoisomerase, an enzyme involved in the supercoiling of chromosomal 
DNA, an essential function in the division of bacteria. In Gram-positive bacteria Topoisomerase 
IV has also been suggested to be the primary intracellular target for fluoroquinolones. 
Topoisomerase IV facilitates the separation of bacterial genomes into daughter cells, another 
essential function for bacterial cell division 10, 47.  
DNA gyrase exists as a tetramer of approximately 370 kDa, made up of two subunits of gyrA and 
two subunits of gyrB48, shown in figures 10 and 11. Spontaneous mutation in the gyrA subunit is 
the most common route to fluoroquinolone resistance, although it has been suggested that 
mutations in both gyrA and gyrB subunits simultaneously is unlikely 49. This makes DNA gyrase a 
good target for a dimeric drug.   
 
 
Figure 10: structure of fluoroquinolone target molecule50, 51; DNA gyrase. DNA gyrase is a dimer 











Figure 11: left: structure of the DNA gyrase dimer 53. Right (top): a close-up of the two 
recognition helices at the 'head dimer interface', viewed from the top with the side chains of 
residues 81, 87, 122 shown (generated with MolScript). Right (bottom): linked fluoroquinolone 
dimer52. 
1.4.2  Antimicrobial properties  
 
Both symmetric and asymmetric fluoroquinolone dimers have been synthesised using a range 
of fluoroquinolone monomers including ciprofloxacin, pipemidic acid, and norfloxacin. The 
antimicrobial properties of these molecules do not correlate with the relative antimicrobial 
properties of the parent fluoroquinolone 54. Asymmetric fluoroquinolone dimers are more 
effective against a range of strains of bacteria than symmetric complexes23, 43, 55, if a strain of 
bacteria develops a resistance to one of the fluoroquinolone monomers, it may still be 
susceptible to the other fluoroquinolone in the asymmetric dimer. Complexes containing a 
ciprofloxacin monomer have been found to be the most potent45, 55.  
The effects of a range of different linkers used in fluoroquinolone dimers indicate that the linker 
plays a pivotal role in the antimicrobial effectiveness of the complexes. Different piperazinyl 
linkers (figure 12) have been found to have antibacterial properties in fluoroquinolone resistant 
strains of bacteria45, 54, 56, a 100 fold reduction in MIC against strains of fluoroquinolone sensitive 
bacteria56, and inhibited growth (but did not kill) strains of Mycobacterium smegmatis 57. Amino 
binds close to pos. 87 
(C-terminus of the
recognition helix)

























acid-based linkers have also been suggested to show decreased degradation inside the bacterial 
cell, giving an increased concentration of the dimer in the cell, relative to the concentration of 
the dimer administered, thereby reducing the MIC55. Although the successfulness of the linker 
is related to its combination of fluoroquinolones in a dimer, the same linker may not be as 
effective with a different combination of fluoroquinolones54. This is due to the size of the 
complex, the linker needs to be able to bridge between the fluoroquinolone donor atoms 
between the DNA gyrase target sites. Different combinations of fluoroquinolones will alter the 

















Figure 12: piperazinyl linkers used in effective antibiotic fluoroquinolone dimers: (7) p-xylene (8) 
m-xylene (9) 2,6-dimethylpyridine (10) (E)-but-2-ene (11) 1,1-biphenyl. Fluoroquinolones with 
piperazinyl groups in the R2 position can be bonded to linkers to form dimeric fluoroquinolone 
molecules, as shown in the molecule at the top of the figure. The linkers (structures 7-11) bond 
to fluoroquinolones in the positions labelled “FQ”. 
Fluoroquinolone mechanism of action involves binding to DNA gyrase. DNA gyrase exists as a 
dimer, consisting of gryA and gryB49, in bacterial strains which are fluoroquinolone resistant, it 
has been found that there is a mutation in either gyrA or gyrB, but not both53, 54. This could 
explain why some of the discussed fluoroquinolone dimer complexes are effective against 
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strains of bacteria which are resistant to fluoroquinolones, as a dimer means that both gryA and 
gryB sites can be targeted simultaneously, therefore if there is a mutation in one subunit, the 
other can still bind effectively with a fluoroquinolone. Furthermore, a bulky sidechain at C7 can 
also overcome efflux mutations in bacteria which are fluoroquinolone resistant 43.  
1.4.3 Anti-tumour properties 
 
An anti-tumour drug that also exhibits anti-microbial properties would have significant clinical 
advantages. Often, a side-effect of cancer treatments is a weakened immune system, which can 
lead to complications from greater pathogenic bacterial susceptibility 58. Fluoroquinolones with 
modifications at the piperazinyl ring, both when coordinated to a transition metal ion58 and 
without metal ion coordination59, 60 have been shown to have anti-tumour properties, through 
their interactions with human topoisomerase II. Topoisomerase II is a class of enzymes used in 
DNA replication in human cells and is often the intracellular target for anti-cancer drug 
compounds 61.  
Fluoroquinolone dimers have displayed anti-tumour properties, which are not observed in the 
parent fluoroquinolone monomers 55. Two ciprofloxacin dimers (with (CH2)14 and 
(CH2OCO(CH2)14COOCH2 piperazinyl linkers) were found to be ineffective as antibacterial agents 
but had an IC50< 10 M MIC against tumour cells62.  
 A further fluoroquinolone dimer has also been synthesised with anti-tumour activity, but this 
dimer is linked though C3 of the fluoroquinolone monomers rather than through the piperazinyl 
groups, as previously seen (figure 13)63.  
 
 
Figure 13: synthesised fluoroquinolone dimer with linker at the C3 position, which has anti-
tumour properties 63. 
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1.4.4 Summary and conclusions  
 
Dimeric fluoroquinolone complexes have potential to overcome fluoroquinolone resistance and 
may have enhanced antimicrobial properties over their fluoroquinolone monomers. There is 
scope to synthesise a range of symmetric and asymmetric compounds with different 
combinations of fluoroquinolones and linkers 23, 55, 43. The linkers are also important to the 
effectiveness of the dimeric complexes 45, 54, 56. As well as antimicrobial properties, dimeric 




2. Metallo-ciprofloxacin complexes: results and discussion  
2.1 Aims and objectives 
 
The aim of this section of work was to synthesise and characterise metallo-fluoroquinolone 
complexes to provide a basis for further investigation of their antimicrobial properties. In order 
to achieve this aim, a review of the existing literature detailing the synthesis of metallo-
fluoroquinolones was undertaken. Repeats of existing synthetic protocols for further 
characterisation and evaluation of the products were carried out, resulting in the synthesis of a 
1:3 bismuth(III)-ciprofloxacin complex and a novel 1:1 zinc(II)-ciprofloxacin complex. In addition, 
by using literature information and preliminary experiments into suitable reaction conditions, 
the synthesis of novel iron(III)-ciprofloxacin complexes was achieved. The iron(III)-ciprofloxacin 
complexes were subsequently characterised and evaluated in comparison to literature metallo-
ciprofloxacin complexes.  
2.2 Introduction  
 
Whilst there has been extensive research into metallo-fluoroquinolone complexes, there are 
few examples of X-ray crystal structures in which metal ions directly bound to fluoroquinolones. 
A literature search for X-ray crystal structures which contained ciprofloxacin was undertaken 
using the Cambridge Structural Database (CSD) from the physical sciences data-science service64. 
A search of the compound name “ciprofloxacin” found 124 X-ray crystal structures. It was found 
that 23 of these structures were metallo-ciprofloxacin complexes with coordination to the metal 
ion through the oxygen donor atoms of the ketone and carboxylate group in ciprofloxacin. The 
metallo-ciprofloxacin complexes identified in the CSD search are summarised in table 9, along 
with key data such as the metal-ciprofloxacin bond lengths of the ketone and carboxylate 








Table 9:  a summary of relevant data from the results of a ciprofloxacin compound search 
using the CSD. The complexes included in this table are metallo-ciprofloxacin complexes 
whereby ciprofloxacin coordination to the metal ion takes place through the ketone and 
carboxylate oxygen donor atoms of the ciprofloxacin ligands*.  











Cd(II) 2.18(2) 2.23(2) 79.9(5) Na2[(Cd(cf)3)(Cd(cf)3(H2O))].12H2O 65 
Co(II) 2.0733(17) 2.0610(19) 86.80(7)  [Co(cf)2].4H2O 66 
Co(II) 2.044(1) 2.052(1) / [Co(cfH)(oba)(H2O)2] 67 
Co(II) 2.013(8) 2.038(8) 87.4(3) [Co(CfH)2(H2O)2].9H2O 65 
Cu(II) 1.9407(19) 1.913(2) 94.03(9) [Cu(cfH)(phen)Cl)](BF4).4H2O 68 
Cu(II) 1.9454 (12) 1.9143 (13) 93.67 (5) [CuCl(cfH)(phen)]Cl.2H2O 69 
Cu(II) 1.9290(15) 1.9333(16) 86.87(7) [Cu(cfH)2Cl2].2MeOH.6H2O 70 
Cu(II) 1.9381(17) 1.917(2) 92.97(8) [Cu(cfH)2(ClO4)2].6H2O 31 
Cu(II) 1.9393(3) 1.9128(3) / [Cu(cfH)(H2O)3]SO4.2H2O 71 
Cu(II) 1.9281(13) 1.9330(14) 86.73(6) [Cu(cfH)2(OH)2].2CH3OH.6H2O 72 
Cu(II) 1.9121(18) 1.917(2) 92.86(8) [Cu(cfH)2(NO3)2].H2O 73 
Cu(II) 1.927(2) 1.907(3) 93.83(10) [Cu(cfH)2(BF4)2].6H2O 74 
Fe(III) 1.9989(16) 1.9678(18) 88.20(7) [Fe(cfH).(C2O4)].(cfH2).5H2O 66 
Mg(II) 2.102(2) 2.038(2) 84.39(7) [Mg(cfH)3](SO4).5H2O  75 
Mg(II) 2.041(1) 2.039(2) 86.04(5) [Mg(H2O)2(cfH)2](NO3)2.2H2O 75 
Mn(II) 2.1578(18) 2.139(2) 83.39(7) [Mn(cfH)2].2H2O 76 
Ni(II) 2.003(1) 2.024(1) / [Ni(cfH)(oba)(H2O)2] 67 
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Ru(II) 2.0897(17) 2.0875(17) 86.10(7)  [Ru(η6-p-cym)(cfA-H)Cl] 58 
Sm(III) 2.345(3) 2.333(3) 72.43(10) [Sm(cfH)(Ox)2] 77 
Sn(II) 2.158 2.135 79.93 Ph2Sn(cfH)2 78 
Zn(II) 1.9994(12) 1.9423(13) 92.73(5) [Zn(cfH)(Hbtc)].H2O 79 
Zn(II) 1.983(16) 2.013(17) 90.6(7) [Zn(cfH)2(H2O)2].8H2O 65 
Zn(II) 2.028(2) 1.920(3) 92.89(10) [Zn2(cfH)2(odpa)] 79 
* ligand abbreviations: cfH=zwitterionic ciprofloxacin, phen=phenethylamine, oba=2-(oxalyl-
amino)-benzoic acid, cym=cymene, cfA=7-(4-(decanoyl)piperazin-1-yl)-ciprofloxacin, 
odpa=octadecylphosphonic acid, Ox=oxalate, btc=trimesic acid.  
 
 
The data obtained from the crystal structures of the metallo-ciprofloxacin complexes identified 
in the ciprofloxacin compound search was used to determine whether there is a correlation 
between the charge density of the metal ion in the complex and the strength of the metallo-
ciprofloxacin coordination, evaluated using the metal-oxygen donor atom bond lengths. The 
volume charge density (ρ) of the metal ions was calculated using equation 180, giving the values 
for each of the metal ions found to be in metal-ciprofloxacin complexes as summarised in table 
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Table 10: formal charges (q) and ionic radii (r) 81 of selected metal ions, used to calculate 
charge densities (ρ) of the metal ions.  
Metal ion Q r/ Å ρ/ Å-3 
Sm(III) +3 1.10 0.54 
Cd(II) +2 0.92 0.61 
Mn(II) +2 0.80 0.93 
Co(II) +2 0.79 0.96 
Zn(II) +2 0.74 1.18 
Cu(II) +2 0.71 1.33 
Mg(II) +2 0.71 1.33 
Sn(II) +2 0.69 1.45 
Ni(II) +2 0.69 1.45 
Ru(II) +2 0.68 1.52 
Fe(III) +3 0.72 1.92 
 
The average lengths of the metal-ketone and metal-carboxylate bonds in the X-ray crystal 
structures of the metallo-ciprofloxacin complexes as a function of the estimated charge density 
of selected metals are shown in figure 14. Whilst it would be expected that the metal-
carboxylate bond lengths would generally be shorter than the metal-ketone bond lengths 
because the oxygen donor atom in the carboxylate group has a formal negative charge, this is 
not observed across all of the metallo-ciprofloxacin complexes reported. It would also be 
expected that as the charge density of the metal ions increases, there would be a stronger 
coordination to the ciprofloxacin ligand, which would be reflected through a shortening of the 
M-O bond lengths. This trend is observed from Sm(II) to Cu(II) with both the metal-ketone and 
metal carboxylate bonds, as shown in figure 14. However, even though Mg(II) has the same 
calculated charge density as Cu(II), the averaged Mg(II) M-O bond lengths (for both ketone and 
carboxylate) are significantly longer. This could be because Mg(II) is an alkaline earth metal 
rather than a transition metal and does not have d electrons available to participate in bonding 
with a ciprofloxacin ligand. A lack of d electron availability to participate in bonding with a 
ciprofloxacin ligand could also explain the Sn(II) metallo-ciprofloxacin M-O bond length 
discrepancy as Sn(II) is a not a transition metal ion. As the charge density of the metal ions 
increases from Mg(II) to Fe(III), coordination to the ciprofloxacin ligand becomes more 
electrostatic than covalent. Differences in the observed and predicted trends in this data will 
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also arise from the influence of the coordination number, different types ligands or 
modifications to the ciprofloxacin ligands in the metallo-ciprofloxacin complexes which have 
been discussed.  
 
Figure 14: graph of the relationship between the mean M-O bond lengths in published metallo-
ciprofloxacin complexes and the charge density (ρ) of metal ions. The error bars plotted are the 
mean maximum and minimum values from the published data. The metal-ketone (black) and 
metal-carboxylate oxygen (red) bond lengths are plotted separately for comparison. 
The data summarised in table 9 also shows the bite angle for the O-M-O bonds of the metal ion 
and the ciprofloxacin oxygen donor atoms. When plotted against the metal ions in order of 
increasing charge density, there is a trend in the O-M-O bond angles as shown in figure 15. In 
perfectly octahedral complexes, it would be expected that the O-M-O bond angle would be 90 
 ͦ, however steric and electronic effects can cause distortion. The mean O-M-O bond angle in 
Cu(II) metallo-ciprofloxacin complexes appears to show the least distortion on the O-M-O bond 
angles with the mean bite angle of 91.14(8)  ͦ. The Sm(III) metallo-ciprofloxacin complex exhibits 
the most distortion of the metallo-ciprofloxacin complexes with a bite angle of 72.43(10)   ͦ. The 
bite angle increases as the charge density of the metal ions increases from Sm(III) to Zn(II), but 












































from Cu(II) to Fe(III) no trend is observed. Once again, this could be due to the influence of the 
coordination number, different types ligands or modifications to the ciprofloxacin ligands in the 
metallo-ciprofloxacin complexes. 
 
Figure 15: graph showing the relationship between metal ion charge density (increasing from 
Sm(III) to Fe(III)) and the O-M-O bite angle in metallo-ciprofloxacin complexes. 
 The results of the literature search for X-ray crystal structures of metallo-ciprofloxacin 
complexes using the CSD have shown that there is potential to coordinate ciprofloxacin ligands 
to a variety of metal ions. Whilst ciprofloxacin is known to have antimicrobial properties, other 
weakly coordinated ligands in the metallo-ciprofloxacin complexes could have additional 
antimicrobial effects via the formation of reactive oxygen species. Reactive oxygen species can 
kill cells if the oxidation process becomes uncontrolled and the production of reactive oxygen 
species is in fact a bacterial mechanism for stress stimulated self-destruction82.  The remainder 
of this chapter will discuss the synthesis and characterisation of further metallo-ciprofloxacin 
complexes.                                                                                








































2.3 Iron(III)-ciprofloxacin  
Iron is essential for fundamental biological processes in almost all living organisms, including 
bacteria. Iron is required for many metabolic functions such as DNA replication, oxygen 
transportation and immune responses 83. Both Gram negative and Gram positive bacteria have 
a variety of iron uptake pathways using various transport proteins, which are summarised in 
figures 16 and 17, using iron sources such as transferrin, hemophores and siderophores. Whilst 
bacteria have numerous iron uptake mechanisms, utilisation of these mechanisms would 
require the membrane receptors to recognise the iron(III)-ciprofloxacin complex, which is 
unlikely as these uptake pathways are specific.  
 
Figure 16: iron uptake mechanism in Gram positive bacteria whereby iron in heme, siderophore 
or transferrin is taken into the cell by membrane-anchored binding proteins and permease 
proteins and is then released as iron(III) after reacting with ATP in ATP-binding cassette proteins. 




Figure 17: iron uptake mechanisms in Gram negative bacteria. Various outer membrane proteins 
are used to transport iron(III) in the form of transferrin, iron-bound siderophores and heme 
groups into the periplasm, which are then bound to periplasmic binding proteins which facilitate 
the transportation into the cytoplasm and through ATP-binding cassette proteins to release 
iron(III) into the cytoplasm. This figure was adapted from a figure by K. D. Krewulak and H. J. 
Vogel84. 
More likely uptake mechanisms into bacteria for the iron(III)-ciprofloxacin complexes will 
involve passive membrane diffusion and porins. Porins (figure 18) are beta barrel proteins found 
in the cell membrane (outer membrane of Gram-negative bacteria) and act as channels for 
passive diffusion.   
 
Figure 18: protein structure of a porin by M. S. Weiss and G. E. Schulz85 (generated with 
Discovery Studio Visualizer). 
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Only one example of an X-ray crystal structure of an iron(III)-ciprofloxacin crystal structure was 
found in a search of CSD, this is [Fe(cfH).(C2O4)].(cfH2+).5H2O (figure 19), which has increased 
antimicrobial activity against  P. aeruginosa than ciprofloxacin at every concentration tested 
(0.125, 0.25 and 0.5 µg mL−1)66, demonstrating the potential for iron(III)-ciprofloxacin complexes 
as antimicrobial agents.  
 
Figure 19: structure of [Fe(cfH).(C2O4)].(cfH2+).5H2O, from crystallographic data reported by L.-C. 
Yu et al.66 
2.3.1 Preliminary experiments 
   
Optimum metal-to-ligand ratio for coordination of iron(III) to ciprofloxacin  
 
In order to determine the optimum metal-to-ligand ratio, a Job’s plot style investigation was 
conducted using UV-vis spectroscopy, the results of which are plotted in figure 20. The 
absorbance at 456 nm was chosen for analysis as this absorption band occurred exclusively in 
the spectra of the solutions between 0.1 and 0.9 molar fraction of ciprofloxacin, suggesting that 
this absorption band corresponds to an electronic transition that is characteristic for the iron(III)  
ciprofloxacin complex. In the pH 2 solution, the maximum absorbance values at 456 nm, 
averaged over results in triplicate, occurred in the 0.5 molar fraction of the ciprofloxacin 
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solution. From this experiment it can be concluded that a 1:1 metal-to-ciprofloxacin ratio is the 
optimum ratio in a pH 2 solution. However, in pH 3 solutions of the same concentration, the 
maximum absorbance shifts further towards a 1:2 iron(III)-to-ciprofloxacin ratio, suggesting that 
the pH influences the ratio of iron and ciprofloxacin complexation.  























Figure 20: Job’s plot graph showing the relationship between pH and molar fraction of 
ciprofloxacin on absorbance at 456 nm. The concentrations of the metal and ligand solutions 
were 1.81 x10-3 mol dm-3 each in hydrochloric acid (0.1 M for pH 2 and 0.02 M for pH 3). The 
results plotted are the mean of the triplicate results at each pH, with the error bars showing ± 
one standard deviation. The experimental procedure is detailed in section 6.2.1. 
From this investigation, it can be concluded that the optimum metal-to-ligand ratio for iron(III)-
ciprofloxacin ratio is dependent on the pH of the solution and further investigation into the pH 
is required. At pH 2, a 1:1 ratio should be employed, whereas a greater metal-to-ligand ratio 
may be appropriate in solutions of a higher pH.  
Extrapolation of the data for each of the Job’s plot graphs at pH 2 and 3 (figure 21) allowed for 
the calculation of the theoretical concentration of the iron(III) ciprofloxacin complex at 100% 
complexation134. Using the theoretical concentration of the iron(III) ciprofloxacin complex at 
100% complexation, a value for the molar extinction coefficient (ε) was calculated using 
equation 2 to be 2078.40 dm3 mol-1 cm-1 for pH 2 and 1705.50 dm3 mol-1 cm-1 for pH 3. The 
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calculated values for ε can then be used to calculate an equillibrium constant (Keq) for the 
reactions at pH 2 and pH 3. 
 
 
Figure 21: Job’s plot graphs showing extrapolated data points used to calculate the values of ε 
and subsequently Keq for iron(III)-ciprofloxacin systems at pH 2 (left) and pH 3 (right). 
 
Equation 2 
𝐴 =  𝜀𝑐𝑙 
 
Using equation 3, Keq is calculated to be 6664.97 mol-1 dm3 for the reaction at pH 2 and 6380.34 
mol-1 dm3 at pH 3. Both values of Keq demonstrate that under the Job’s plot experimental 
conditions (room temperature, atmospheric pressure), the equillibrium favours the product 
(iron(III)-ciprofloxacin complex) over the reactants. Whilst the values for Keq for both the pH 2 
and pH 3 systems are of a similar magnitude, there is a greater value for Keq calculated for the 
pH 2 system than the pH 3 system, evidencing that there is more iron(III)-ciprofloxacin 





[𝑀] = [𝑀] − [𝑀𝐿]  
[𝑀] = [𝑀] − [𝑀𝐿]  
               [𝐿] = [𝐿] − [𝑀𝐿]  
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Optimum pH for complexation  
 
Coordination to iron(III) is expected to occur at the hard oxygen donor atoms of the ketone/ 
carboxylate groups in ciprofloxacin. Figure 22 demonstrates that pH impacts the species of 
ciprofloxacin present. At pH 6.35 half of the carboxylic acid groups in ciprofloxacin are 
deprotonated86, making it a better donor atom and therefore more likely to coordinate to 
iron(III); a hard metal ion. However, it is difficult to get iron(III) ions in solution in basic 
conditions, due to their Lewis acidic properties they tend to precipitate as hydroxides. Figure 22 
also shows that around neutral pH, the zwitterion of ciprofloxacin is present which is insoluble.  
This knowledge directed the research into the investigation of metallo-fluoroquinolone 
complexation in acidic conditions.  
 
Figure 22: scheme showing the varying pKa values of ciprofloxacin 86. 
Solutions with pH values of less than two could not be evaluated as ciprofloxacin was found to 
be fully protonated and insoluble below pH 2. Similarly, solutions with pH values greater than 
four could also not be investigated due to insolubility of both iron(III) and ciprofloxacin.  
The findings from the  Job’s plot investigation into iron(III)-ciprofloxacin coordination presented 
in figure 20 show that pH influences the absorbance at 456 nm. Greater absorbance occurs for 
the solutions of the same concentration and the same molar fractions at pH 2 comparative to 
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pH 3. The positive correlation between absorbance and concentration, demonstrated in the 
Beer-Lambert Law (equation 2) suggests that there is a greater concentration of the iron(III)-
ciprofloxacin complex in solution at pH 2 versus pH 3 
These findings allude to a solution of pH 2 creating more optimum reaction conditions compared 
to a solution of pH 3. Using a pH probe, it was found that ciprofloxacin in 0.1 M hydrochloric acid 
solution has a value of pH 2 and therefore this provided the basis of the reaction conditions used 
for metallo-fluoroquinolone complexation.  
2.3.2 Crystallisation Techniques 
 
A critical objective of this research is to show that the metal ion is coordinated to the 
fluoroquinolone molecule in the synthesised complexes. This is important as literature suggests 
that merely the presence of unbound metals does not influence the effectiveness of 
fluoroquinolone antibiotics 37-39. Given the poor solubility of the reagents and resulting 
complexes, characterisation is challenging. Creating a good quality crystal allows for a crystal 
structure to be generated to determine the structure of the complex.  
Solvent Layering   
 
Solvent layering is a commonly used crystallisation techniques. A range of anti-solvents were 
tested to find the most suitable. In the synthesis of the iron(III)-ciprofloxacin complex, acetone, 
acetonitrile and methanol were selected due to their miscibility with water (the solvent of the 
reaction mixture). Of the anti-solvents employed, solvent layering with acetone was the only 
anti-solvent to yield a precipitate. However, this technique yielded powders/ microcrystals, 
which were not suitable for analysis via X-ray crystallography. In order to create more useful 
crystals for analysis, experimentation with other crystallisation techniques were carried out in 
order to slow down the crystal growing process.    
Vapour Diffusion  
 
Vapour diffusion crystallisation was the most successful crystallisation technique and yielded 
crystals which were analysed using X-ray crystallography. Using the knowledge acquired from 
the solvent layering experiments, acetone was the antisolvent of choice for the iron(III)-
ciprofloxacin experiments. Acetone is also volatile, a key feature required for an anti-solvent in 
vapour diffusion. The set up for this solvent diffusion method was using an open small sample 
vial (1.8 mL), half filled with the reaction mixture, inside a tightly sealed larger sample vial (8 mL) 
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containing the antisolvent, as shown in figure 23. This set up was more successful than solvent 
layering for creating crystals, but some of these crystals were still not of a quality that could be 
analysed using X-ray crystallography. Care was taken to ensure that the crystallisations were set 
up at room temperature in places where they would be undisturbed.   
 
 
Figure 23: solvent vapour diffusion crystallisation method set up using an open smaller sample 
vial (1.8 mL) half filled with the reaction mixture (approx. 1 mL), inside a tightly sealed larger 
sample vial (8mL) containing the antisolvent (approx. 1 mL). 
 
2.3.3 Synthesised iron(III)-ciprofloxacin complexes  
 
Two different iron(III)-ciprofloxacin complexes have been synthesised using the information 
from the preliminary experiments into iron(III)-ciprofloxacin coordination, and their crystal 
structures have been analysed in comparison to a crystal structure of the isolated ciprofloxacin 
ligand (2). The first iron(III)-ciprofloxacin complex to be synthesised was [FeCl(H2O)(cfH)] (1). In 
order to remove the chloride ligand iron(III) sulfate was used as opposed to iron(III) chloride in 
the synthesis of the second iron(III)-ciprofloxacin complex, the complex salt   
[Fe(SO4)(H2O)3(cfH)]+ [Fe(SO4)2(cfH)2]-(3).  
2.3.3.1 Iron(III) chloride-ciprofloxacin complex  
 
The first complex to be successfully crystallised and analysed using X-ray crystallography was the 
1:2 iron(III)-ciprofloxacin complex (1), the crystal structure is shown in figure 24. The crystal data 
Tightly sealed larger 






(approx. 1 mL) 
Antisolvent 
(approx. 1 mL) 
50 
 
and refinement of (1) was generated by Dr Adrian C. Whitwood. This complex was formed using 
non-stoichiometric quantities of ciprofloxacin and iron(III) chloride hexahydrate (equation 4) 
and was crystallised using vapour diffusion with acetone. Single crystal X-ray diffraction shows 
that the 1:2 iron(III)-ciprofloxacin crystals have a monoclinic crystal system with an I2/a space 
group. A discrete atom model was used to model disordered solvent and anions in this crystal 
and a solvent mask was used in order to account for the 64 electrons of disordered content per 
complex which lay in a solvent channel. The highly disordered solvent content of this crystal 
equated to a combination between 2 acetone and 6 water molecules. Three different 1:2 
iron(III)-ciprofloxacin complexes exist in this crystal structure, with variation in the chloro/ aquo 
ligands. Present in the crystal are a combination on dichloro, diaquo and chloro/aquo complexes 
with a chloride to water ratio of 0.373:0.626(6).  The second ciprofloxacin ligand is symmetry 












Table 11: selected bond lengths for 1:2 iron(III)-ciprofloxacin (1).  
Atom  Atom Length/Å   Atom  Atom Length/Å 
C1 O1 1.275(3)   Cl1  Fe2 2.293(3) 
C1 O2 1.246(3)   Fe2  O1 1.997(16) 
C3 O3 1.279(3)   Fe2  O3 2.029(15) 
 
Table 12: selected bond angles for the crystal structure of (1). 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
O1 C1 C2 119.20(19)   O1 Fe2 Cl1 96.65(8) 
O2 C1 C2 118.70(2)   O1 Fe2 O3 84.99(6) 
O2 C1 O1 122.10(2)   O1 Fe2 O4 97.03(16) 
O3 C3 C2 124.27(19)   O3 Fe2 Cl1 97.20(9) 
O3 C3 C4 118.99(19)   O4 Fe2 O3 85.78(17) 
C1 O1 Fe2 128.29(14) C3 O3 Fe2 121.86(13) 
 
 
Figure 24: ORTEP representation of the asymmetric unit of 1:2 iron(III)-ciprofloxacin (1). 
Ellipsoids are plotted at 50 % probability 
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With a coordination number of six and metal-ligand bond angles around 90˚, (1) has an 
approximately octahedral geometry. The bond lengths obtained for the 1:2 iron(III)-
ciprofloxacin complex yielded from the reaction detailed in equation 4, shown in table 11, show 
that the longest bond in this structure is the Fe2-O3 bond (2.0292(15) Å). This coincides with 
what would be expected as this is a particularly weak coordination, as the O3 atom is from the 
ketone group on the ciprofloxacin ligand and does not have a formal negative charge and 
therefore does not engage strongly in electrostatic interactions.  
The deprotonated O1 atom is a hard donor atom, which according to hard-soft acid-base theory, 
will have a high affinity for the iron(III) ion which is a hard acceptor. Furthermore, the 
deprotonated O1 has a negative charge and therefore mainly interacts with the positively 
charged iron(III) ion through strong electrostatic interactions. This explains why the Fe2-O1 bond 
is shorter and therefore stronger than the Fe2-O3 bond (1.997(16) Å versus 2.029(15) Å). The 
equivalent of M-O1 forming a shorter bond than M-O3 is also observed in a copper(II) complex 
with a modified ciprofloxacin ligand 60, 87 in which the ciprofloxacin ligand is coordinated to the 
copper ion through the oxygen donor atoms in the β-ketone carboxylic acid group. The bond 
lengths of Fe2-O1 and Fe2-O3 are within error of the reported bond lengths of ciprofloxacin to 
iron(III) by Wallis et al. for their complex: [Fe(cf-)(nta)]3.5H2O (this complex was not reported in 
CSD). The equivalent of the Fe2-O1 bond length in [Fe(cf-)(nta)]3.5H2O was found to be 1.97(1) 
Å compared to 1.997(16) Å in (1). Similarly, the equivalent of the Fe2-O3 bond in [Fe(cf-
)(nta)]3.5H2O was found to be 1.942(8) Å compared to 2.029(15) Å in (1)13. The biological 
consequences of the strength of the coordination of the ciprofloxacin ligand to the iron(III) ion 
will depend on the mechanism of action of the drug molecule in bacterial cells. As the 
ciprofloxacin pharmacophore structure-activity-relationship requires the β-ketone carboxylic 
acid group for coordination to the intercellular target molecule; DNA gyrase and for bacterial 
transport, a more labile ciprofloxacin ligand could be advantageous.  
The Fe2-Cl1 bond length (2.293(3) Å) in (1) is slightly longer than reported literature values for 
Fe(III)-Cl bonds88, 89. The occasional occupancy of chloro ligands on the iron(III) ion poses as a 
problem as this means that there is not a uniform structure throughout the crystal and as such 






Figure 25: ball and stick representation of the asymmetric unit of (1) with the bond angle of O3-
Fe2-O1 measured to be 84.99(6) ˚. Solvent atoms and hydrogen atoms have been removed for 
clarity. 
Figure 25 shows that the O1-Fe(III)-O3 bond angle is 84.99(6)˚, which is smaller than the 90˚ 
angle expected in the octahedral structure, meaning that there is distortion. Distortion could be 
caused by steric or electronic effects driven by the ligands.  
 
 
Figure 26: wire representation of (1) with the pi stacking distance of the aromatic rings of the 
ciprofloxacin ligands measured to be 3.850 Å between the C2/C3/N1/C4/C9/C10 rings and 5.209 
Å  between the C4/C5/C6/C7/C8/C9 rings, using calculated centroid atoms. Solvent atoms and 
hydrogen atoms have been omitted for clarity. 
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There is π- π stacking present in (1). The ciprofloxacin ligands are stacked over each other due 
to the π- π stacking interactions between the aromatic rings in the ciprofloxacin ligands and also 
due to the drive for the hydrophobic ciprofloxacin ligands to align. Using calculated centroids, 
as displayed in figure 26, the π- π stacking distance of the C2/C3/N1/C4/C9/C10 aromatic rings 
of the ciprofloxacin ligands to be 3.850 Å. The distance between the C4/C5/C6/C7/C8/C9 
aromatic rings in ciprofloxacin experience less π- π stacking interaction shown by the longer 
distance of 5.209 Å. The reasons for the reduced π- π stacking interaction in the 
C4/C5/C6/C7/C8/C9 aromatic rings in the ciprofloxacin ligands could be due to steric factors 
meaning that the rings simply do not align as well as the C2/C3/N1/C4/C9/C10 aromatic rings. 
Another explanation for the reduced π- π stacking interaction in the C4/C5/C6/C7/C8/C9 
aromatic rings in the ciprofloxacin ligands is the fluorine substituent that is present, which is 
very electronegative and therefore reduces the electron density surrounding the aromatic ring.  
π- π stacking is not observed between intramolecular ciprofloxacin ligands in the metallo-
ciprofloxacin structures found in the CSD search. This is because the complexes that were found 
in the CSD search either only had a single ciprofloxacin ligand, or because the ciprofloxacin 
ligands are trans to one another and therefore are not close enough nor have a favourable 
orientation to interact.  
All of the bond lengths and angles of the ciprofloxacin ligand in (1) are comparable within error 
to those of the uncoordinated ciprofloxacin ligand (2), with the exception of the carbonyl group  
bond lengths. In (1) there is a carboxylate group where there is a carboxylic acid group in (2). In 
comparison to the uncoordinated ciprofloxacin ligand (2) shown in figure 27, the C1-O1 bond in 
(1) is significantly shorter (1.275(3) Å in (1) and 1.3329(15) Å in (2)) and the C1-O2 bond is 
significantly longer (1.246(3) Å in (1) and 1.2124 Å in (2)). The changes in the carboxylate bond 
lengths arise due to the coordination of the O1 ion to the iron(III) ion. Although the ketone 
oxygen atom in ciprofloxacin (O3) also takes part on coordination to the iron(III) ion, there is no 
significant difference between the C3-O3 bond lengths of the ketone in the coordinated and 
uncoordinated ciprofloxacin ligand (1.279(3) Å in (1) and 1.2700(15) Å in (2)), which further 





Figure 27:  ORTEP representation of the X-ray crystal structure of ciprofloxacin (2). Ellipsoids are 
plotted at 50 % probability. C15A, C17A and C18A have been omitted for clarity, these formed a 
minor structure within the crystal with a ratio of the occupancy of the major and minor 
structures of 0.931:0.069(3). This structure was collected and refined by Adrian C Whitwood. 
Table 13: selected bond lengths for ciprofloxacin (2). 
Atom  Atom Length/Å Atom Atom Length/Å 
C1 C2 1.4891(16) C1 O2 1.2124(15) 
C1 O1 1.3329(15) C3 O3 1.2700(15) 
 
There are intermolecular interactions between the molecules of (1), these interactions are 
shown in figure 28. Intermolecular hydrogen bonding exists between F1 and H10. The C6 carbon 
atom in (1), which is bonded to the F1 atom is sp2 hybridised. C(sp2)-F bonds are weaker than 
C(sp3)-F bonds 90.  C(sp2)-F fluorine atoms cannot enter into as strong hydrogen bonding as 
C(sp3)-F fluorine atoms 90, 91 because sp2 orbitals have greater s-orbital character and therefore 
are not as expanded as sp3 orbitals meaning that a lone pair of electrons cannot participate in 
hydrogen bonding as readily in C(sp2)-F. The C(sp2)-F hybridisation explains why hydrogen 
bonding between H10 and F1 has a relatively long contact distance of 3.101 Å. The shortest 
intermolecular interaction occurs between the O2 atom of one molecule and the H3 of another, 





Figure 28: X-ray crystal structure of [FeCl(H2O)(cfH)]  (1), showing the intermolecular 
interactions. Left: ball and stick asymmetric unit of (1) with atom labels showing intermolecular 
interactions. Right: structure of (1) with ellipsoids plotted at 50 % probability, showing 
intermolecular interactions. In both diagrams solvent atoms have been removed for clarity. 
The intermolecular interactions described result in packing of the molecules in a stacking 
formation whereby the molecules of (1) flip alternatively allowing for the more hydrophobic 
piperazinyl groups to group together (figure 29).  
 
 






2.3.3.2 Iron(III) sulfate-ciprofloxacin complex  
 
The chloride ions in the 1:2 iron(III) chloride-ciprofloxacin complex resulted in a mixture of 
molecules with chloro and aquo ligands present in the structure, therefore an alternate iron 
source was used: iron(III) sulfate. This time a 1:2 ratio of iron(III) sulfate, Fe2(SO4)3, and 
ciprofloxacin reaction was used (to maintain the 1:1 iron(III)-to-ciprofloxacin ratio). Using 0.01 
M sulfuric acid (in order to retain the pH 2 condition), the rest of the reaction and crystallisation 
set up was the same as the successful reaction with iron(III) chloride hexahydrate- solvent 
vapour diffusion with acetone. The crystals yielded from this reaction were suitable for X-ray 
crystallography, the X-ray crystallography data for these crystals was collected and refined by 
Theo Tanner. The crystal structure in figure 30 shows that the product is a 1:1 mixture. The 1:2 
iron(III)-ciprofloxacin compound which was present was to be expected based on the results of 
the iron(III) chloride hexahydrate experiments, however the 1:1 iron(III)-ciprofloxacin 
compound was also present in the crystal. The formation of the additional 1:1 iron(III)-
ciprofloxacin complex is likely due to a discrepancy in the moles of iron(III) sulfate that was 
added, this is likely because the iron(III) sulfate was yielded from drying iron(III) sulfate hydrate, 
which had an unknown number of water molecules included. It is possible that there were still 
water molecules present in the iron(III) sulfate, meaning the stoichiometric calculations were 
not accurate and in fact tended more towards a 1:3 iron(III)-ciprofloxacin ratio as detailed by 
the reaction shown in equation 5. As the X-ray crystal data for (3) does not indicate the existence 
of molecules with aquo ligands, the crystal structure is more uniform and therefore the use of 
iron(III) sulfate could be an improved iron source for this reaction. However, the 1:1 iron(III)-
ciprofloxacin complex exists as a cation and the 1:2 iron(III)-ciprofloxacin complex exists as an 

















Figure 30: ORTEP representation of the X-ray crystal structure of (3). Ellipsoids are plotted at 50 
% probability. O20 and O19 (occupancy of 0.44(3)) , C31A, C32A, C33A and C34A (occupancy of 
0.684(6)), and C15A, C16A and C17A (occupancy of 0.361(6)) have been omitted for clarity. Data 
collected and refined by Theo Tanner. 
The crystal system for (3) was found to be triclinic with P-1 space group.. The the structure was 
solved with the ShelXT 92 structure solution program using Intrinsic Phasing and refined with the 
ShelXL93 refinement package using Least Squares minimisation.  
To fully analyse the structures of the two iron(III)-ciprofloxacin complexes, the two complexes 
can be looked at separately and then the crystal structure analysed as a whole. To do this, the 
[Fe(SO4)2(cfH)2]- complex will be referred to as 3i and the [Fe(SO4)(H2O)3(cfH)]+ complex will be 




Figure 31: ORTEP representation of the X-ray crystal structure of the 1:2 iron(III)-ciprofloxacin 
complex found in (3), [Fe(SO4)2(cfH)2]-, henceforth referred to as 3i. Ellipsoids are plotted at 50 
% probability.  O20 and O19 (occupancy of 0.44(3)) , C31A, C32A, C33A and C34A (occupancy of 
0.684(6)), and C15A, C16A and C17A (occupancy of 0.361(6)) have been omitted for clarity. 
3i has six donor atoms coordinated to the iron(III) centre, each with close to a 90˚ angles. As 
expected, the longest bonds in the 3i complex are the Fe2-O15 and Fe2-O11 bonds, with 
distances of 2.052(3) Å and 2.037(3) Å, respectively. These bonds are from the coordination of 
iron(III) to the ketone oxygen in ciprofloxacin, which is the equivalent of the longest bond in (1). 
These particular Fe-O bonds in 3i are within error of the same bond in (1) which is 2.0292(15) Å. 
The O-M-O bite angles of both the ciprofloxacin ligands would be expected to be equivalent in 
each of the ciprofloxacin ligands and close to 90˚. Both the O11-Fe2-O12 (85.47(1) ˚) and O14-
Fe2-O15 (85.61(1) ˚) bond angles are less than 90˚ and what’s more, these angles are not within 
error of each other. The unexpected bite angles are as a result of distortion caused by the steric 




Figure 32: wire frame representation of 3i with measured bond angles for the O-M-O bite angles 
for each of the ciprofloxacin ligands. Solvent and hydrogen atoms have been omitted for clarity. 
As was seen in the crystal structure of (1) the bond length for the coordination of the iron(III) 
ion to the deprotonated oxygen atom on the carboxylic acid is shorter than that to the ketone. 
This is again due to the fact that the deprotonated oxygen atom in the carboxylic acid is a 
negatively charged donor atom, whilst the ketone oxygen atom is neutral and therefore has a 
greater affinity to coordinate to the iron(III) hard acceptor ion. In 3i the Fe2-O14 and Fe2-O11 
bonds are 1.968(3) Å and 2.037(3) Å, respectively.  The Fe2-O14 bond (1.968(3) Å )  is of a similar 
length to that of  Wallis et al. for their complex: [Fe(cfH)(nta)]3.5H2O which was 1.97 Å13. The 
bond length for the equivalent iron(III) oxygen bond in (1) is 1.997(16) Å, which lies between the 
two values for this bond reported in 3i.  
The Fe2-O13 and Fe2-O16 bonds are also amongst the longest bonds in this molecule with 
lengths of 1.987(4) Å and 1.964(4) Å, respectively. This suggests that these ligands could be quite 
weakly bonded, but the important distinction between the molecules in (3) and the molecules 
in (1) is that we do not see any substitution of ligands such as a substitution of a sulfate for aquo 
ligands like we do with the chlorine atom in (1).   
The nitrogen atoms N3 and N6 are protonated and therefore form a cation due compound 
formation under acidic conditions in 0.1 M sulfuric acid.  
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There are π- π stacking interactions between the two ciprofloxacin ligands in 3i. Figure 33 shows 
that using calculated centroid atoms, the distances between the C18/C19/C20/N4/C21/C22 and 
the equivalent C35/C36/N1/C37/C38/C39 aromatic rings is 4.258 Å. The distance between these 
two rings is longer than that of the equivalent rings in (1) (3.850 Å), meaning the π- π stacking 
interaction is weaker. There is also π-π stacking interactions between the 
C21/C22/C27/C28/C29/C30 and C37/C38/C47/C46/C45/C44 aromatic rings in the two 
ciprofloxacin ligands. The distance between to calculated centroids for these rings is 4.250 Å, 
which is comparable to the afore discussed π- π stacking interaction in 3i (4.258 Å). The distance 
of  4.250 Å is significantly shorter than that of the distance between the equivalent ciprofloxacin 
rings in (1), which was 5.209 Å. The shorter distance between the C21/C22/C27/C28/C29/C30 
and C37/C38/C47/C46/C45/C44 aromatic rings in 3i suggests that there is a stronger π- π 
stacking interaction, which is likely due to the steric effects of the other coordinating ligands 
meaning that the ciprofloxacin ligands are in closer proximity to interact.  
 
Figure 33: wire frame representation of 3i, showing the measured distances between calculated 
centroids in the aromatic rings of the ciprofloxacin ligands. The hydrogen and solvent atoms 
have been removed for clarity. 
In 3ii, the iron(III) cation also has six coordination sites, however this complex has three aqua 
ligands, a sulfate ligand and a single bidentate ciprofloxacin ligand, and forms on octahedral 





Figure 34: ORTEP X-ray crystal structure of the 1:1 iron(III)-ciprofloxacin structure found in (3) 
[Fe(SO4)(H2O)3(cfH)]+, henceforth referred to as 3ii.  Ellipsoids are plotted at 50 % probability. 
The longest bonds in this structure are the iron(III)-aqua ligand bonds with the Fe1-O5, Fe1-O4 
and Fe1-O6 bonds being 2.055(3) Å, 2.050(3) Å and 2.020(4) Å respectively. It is to be expected 
that these are the longest bonds in the complex due to a theoretically weak coordination 
between the oxygen donor atom in the aqua ligands and the hard iron(III) ion. These iron(III)-
aqua bong lengths are fall within a range of 1.98-2.11 Å , which has been reported for iron(III)-
aqua bond lengths across several compounds94-105.  
Unsurprisingly, as we have observed in the previously discussed iron(III)-ciprofloxacin complexes 
(1) and 3i, one of the longer bond lengths in the structure of 3ii is the Fe1-O1 bond, with a length 
of 1.964(2) Å, which is similar to that of the length of the equivalent bonds in (1) and 3i. Once 
again the Fe1-O1 bond length is, as expected, longer than the Fe1-O2 which was found to be 
1.952(3) Å.  
The O-M-O bond angle between O1-Fe1-O2 is measured to be 88.91(9) ˚, which is smaller than 
the expected bite angle of 90 ˚, demonstrating that there is distortion in 3ii. However, the bite 
angle in 3ii is closer to 90 ̊  than in 3ii (85.47(1) ̊  and 85.61(1) ̊ ) and (1) (84.99(6) ̊ ), which means 
that 3ii experiences less distortion than 3i and (1). The reason that 3ii experiences less distortion 
than 3i and (1) is because 3ii only has one ciprofloxacin ligand, which is the largest ligand in all 
of the synthesised complexes, which means that there is less steric interaction between the 
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ligands in 3ii. The reduced distortion in 3ii when compared to 3i and (1) highlights the 
significance of steric factors on the distortion of these complexes.  
 
Figure 35: wireframe representation of 3ii with a measured O-M-O bite angle for the 
ciprofloxacin ligand. Hydrogen and solvent atoms have been removed for clarity. 
The rest of the bond lengths and angles in the ciprofloxacin ligand are consistent with those in 




Figure 36: X-ray crystal structure of the 1:1 complex salt of [Fe(SO4)2(cfH)2]-  3i and 
[Fe(SO4)(H2O)3(cfH)]+ 3ii. Ellipsoids plotted at 50 % probability. 
Similar to the observations in (2), in (3) there are several intermolecular interactions between 
the complexes 3i and 3ii structures. Figure 36 shows the packing and illustrates that the 
protonated piperazinyl rings in 3i are interacting with the sulfate groups of the other molecules 
of 3i via hydrogen bonding.  
2.3.3.3 Summary of conclusions from crystallographic information  
 
The X-ray crystallographic structures evidence that two different iron(III)-ciprofloxacin 
complexes have been synthesised. Across both of the complexes it is evident that the iron(III)-
ketone interaction is weaker than the iron(III)-carboxylate interaction, shown by the significantly 
longer bond lengths between the ciprofloxacin ketone oxygen and the iron(III) ion. Both of the 
complexes have distorted octahedral geometries, with distortion arising from the steric and 
electronic effects driven by the ligands. Both complexes also feature π-π stacking interactions 
between the aromatic groups in the ciprofloxacin ligands. The occasional occupancy of chloro 
ligands on the Fe(III) ion in the iron(III) chloride-ciprofloxacin complex raises issues in the future 
applications of this complex as an antimicrobial drug as the complex does not have a uniform 
structure throughout the crystal structure. However, the iron(III) sulfate-ciprofloxacin complex 
does appear to have a uniform structure and therefore could be better suited for applications 
in medicinal chemistry.   
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2.4 Bismuth-ciprofloxacin complex 
 
Similarly to iron(III), bismuth(III) is a hard metal 3+ ion. Whilst bismuth(III) is not essential for life 
and has no naturally occurring biological role, it has been administered alongside antibiotics in 
the treatment of stomach ulcers, although the mechanism of action is largely unknown. 
Although bismuth can be poisonous, the limited solubility of bismuth salts means that it is 
possible for them to be administered safely. There were no examples of published X-ray crystal 
structures of bismuth(III)-ciprofloxacin complexes in a search of the CSD.  
The precursor for the bismuth(III)-ciprofloxacin complexes that are described is bismuth 
oxynitrate. Bismuth oxynitrate is a term used to label a variety of compounds which contain 
bismuth(III) ions, nitrate ions and oxide ions106. The synthesis of bismuth oxynitrate was carried 
out according to a procedure described by B. Lu et al.107. Bismuth oxynitrate exists in a variety 
of forms. The elemental analysis of the synthesised bismuth oxynitrate compound suggests that 
there are only trace amounts of hydrogen in the synthesised compound as one run of the sample 
showed 0 % hydrogen and another measured 0.01 % hydrogen. This suggests that the rest of 
the compound is made up of bismuth(III), nitrogen and oxygen, which is supported by the 
absence of carbon in both runs and an average of 3.62 % nitrogen present.  
2.4.1  1:4 bismuth(III)-ciprofloxacin  
 
An repeated synthesis of a 1:4 bismuth(III)-ciprofloxacin complex following a procedure 
reported for the synthesis of a 1:4 bismuth(III)- norfloxacin complex by A. R. Shaikh et al. 18, with 
the structure reported shown in figure 37. The bismuth(III)-norfloxacin complex synthesised by 
A. R. Shaikh et al. 18 was characterised via IR which showed characteristic norfloxacin bands as 
well as Karl-Fischer titration and elemental analysis, which was consistent with a 1:4 bismuth-
norfloxacin ratio with two aqua ligands. It is acknowledged here that the structure that has been 
suggested by A. R. Shaikh et al.18 would also require a counter ion to balance out the charges.  
Whilst it is not unusual for bismuth(III) to have a high coordination number; the coordination 
number of bismuth(III) typically ranges between two and nine 108, therefore it is unlikely that all 
of the suggested bismuth(III)-ligand coordinations would be possible as this would give a 
coordination number of ten. In the crystal structures of the iron(III)-ciprofloxacin complexes it 
was found that the metal(III) coordination to the aqua ligands and to the β ketone oxygen atom 
were the weakest in the complexes and therefore it could be suggested that these coordinations 
are the most likely to not be present in this compound.  
67 
 
In the repeated synthesis following the procedure reported by A. R. Shaikh et al. 18, with 
ciprofloxacin instead of norfloxacin, X-ray fluoresence (XRF) confirmed the presence of bismuth 
in the compound and IR confirmed the presence of ciprofloxacin. However, the elemental 
analysis for this compound was very different from the theoretical calculation. The calculated 
values for CHN of this reported compound are: C 50.63 %, H 4.78 %, N 11.07 %. However the 
compound that was synthesised using ciprofloxacin in the procedure outlined A. R. Shaikh et 
al.18 elemental analysis found: C 35.33 %, H 4.25 %, N 7.10 %, therefore the repeated compound 
is unlikely to be a 1:4 complex of bismuth(III)-ciprofloxacin.  
 
Figure 37: [Bi(H2O)2(norfloxacin)4] structure proposed by A. R. Shaikh et al.18, for which an 
attempt at the synthesis of a bismuth(III)-ciprofloxacin complex was made. 
2.4.2  1:3 bismuth(III)-ciprofloxacin  
A further attempt at synthesising a bismuth(III)-ciprofloxacin complex was made. The 1:3 
bismuth ciprofloxacin complex was synthesised following a procedure from A. R. Shaikh et al.19, 
in which it is suggested that the structure of this complex is a bismuth(III) ion coordinated to 
three bidentate ciprofloxacin ligands coordinated through the β ketone and deprotonated 
carboxylic acid groups, as well as two water ligands, as shown in figure 38. A. R. Shaikh et al.19 
characterised the 1:3 bismuth(III)-ciprofloxacin complex using elemental analysis, IR and melting 
point.   




Figure 38: the proposed structure of [Bi(H2O)2(cf-)3], synthesised by A. R. Shaikh et al.19 
In the reported experiment, the melting point for this complex was found to be 322–324 ℃, 
which is in agreement with the value found when repeated; 323-326 ℃. The IR for both the 
reported complex by A. R. Shaikh et al.19 and the repeat that is discussed are in agreement and 
suggest the presence of ciprofloxacin in the compound as a result of C-F stretching, carbonyl 
stretching and conjugated alkene stretching peaks. There is also an absence of peaks between 
1722-1707 cm-1, which are associated with the carboxylic acid group of uncoordinated 
ciprofloxacin110. The presence of the water ligands could not be determined in either study as 
the IR spectra are recorded up to 2000 cm-1 and a water O-H stretch would be found at in the 
frequency range 3700-3100 cm-1.  The reported elemental analysis found: C 49.98 %, H 4.99 % 
and N 10.02 % compared to the calculated values for the formula [Bi(H2O)2(cf-)3], which were: C 
49.56 %, H 4.49 %, N 10.20 %. The repeated synthesis values differ to those found in the 
synthesis of [Bi(H2O)2(cf-)3] by A. R. Shaikh et al.19. The CHN results for the repeated synthesis of 
[Bi(H2O)2(cf-)3] were found to be: C 48.69%, H 5.64%, N 9.85%. This discrepancy is likely because 
the repeated sample contained water solvent molecules, which would account for the slightly 
higher percentage of hydrogen in the repeated synthesis. 
Further to the investigation into the structure of the 1:3 bismuth-ciprofloxacin complex by A. R. 
Shaikh et al.19, in the repeat of their synthesis reported and discussed here, further analysis has 
been undertaken using NMR and XRF techniques. 13C, 1H and 19F NMR spectroscopy further 
confirm the presence of ciprofloxacin in this compound as the spectra recorded for this 
compound are consistent with that of the free ciprofloxacin ligand. XRF spectroscopy was 
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employed to confirm the presence of the bismuth ion. Figure 39 shows the results of the XRF 
analysis, which shows a pattern of peaks which are consistent with the characteristic energy 
levels in bismuth. The additional peaks that are observed in this spectrum are consistent with 
that of calcium. The presence of calcium is due to the trace amounts of calcium carbonate on 
the mounting plate.   
 
Figure 39: XRF spectrum of the compound [Bi(H2O)2(cf-)3]. This spectrum confirms the presence 
of bismuth in the product obtained. 
Whilst the analysis techniques that have been described can confirm that in this compound 
there is bismuth and ciprofloxacin present, there is no definitive evidence that the bismuth(III) 
ions have formed a complex with ciprofloxacin. Without a crystal structure this cannot be 
confirmed. One of the challenges this compound has presented is its low solubility, because of 
this, attempts at gaining analysis using mass spectrometry and X-ray crystallography have been 
unsuccessful.  
2.5 Zinc-ciprofloxacin 
Zinc is commonly found in biology 109. Zinc(II) is an intermediate ion in hard-soft acid-base 
theory, which means that it is not as well suited as a hard metal ion like bismuth(III) or iron(III) 
to coordination to the hard donor unprotonated oxygen ion in the carboxylic acid group of 
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ciprofloxacin, however the other coordinating atom in the bidentate ciprofloxacin ligand is the 
relatively softer oxygen atom in the β ketone, therefore coordination of ciprofloxacin to zinc(II) 
is still theoretically possible. This is confirmed by the published X-ray crystal structure of a 
[Zn2(cfH)2(odpa)] complex, which used a 4,4′-oxydiphthalate ligand as well as a ciprofloxacin 
ligand to form a helical structure 79, for which the antimicrobial properties were not tested.  
Following the procedure reported by Z. H. Chohan et al.11 a zinc(II)-ciprofloxacin complex has 
been synthesised. The structure of the complex proposed by Z. H. Chohan et al.40 is of 
[Zn(H2O)2(cf-)2], shown in figure 40.  
 
Figure 40: proposed structure of the [Zn(H2O)2(cf-)2] by Chohan et al.40. 
XRF analysis confirmed that there is zinc present in the compound, the spectrum is shown in 
figure 41. The labelled peaks in figure 41 are consistent with the characteristic energy levels in 
zinc, confirming the presence of zinc in the compound. The additional peaks can be attributed 
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to calcium, from the calcium carbonate present on the mounting plate.
 
Figure 41: XRF spectrum of the compound synthesised following the procedure reported by 
Chohan et al.40 
Due to the poor solubility of the complex, solid state NMR (ssNMR) was used to confirm the 
presence of ciprofloxacin in the complex. Figure 42 shows the proton and carbon decoupled 19F 
ssNMR spectrum with a single resonance at -131 ppm showing the presence of a fluorinated 
compound. The additional peaks observed in the 19F ssNMR spectrum are spurious signals arising 
from spinning side bands. Figure 43 shows the proton decoupled 13C ssNMR spectrum for the 
synthesised zinc(II)-ciprofloxacin complex, which shows resonances consistent with 
ciprofloxacin. Peaks above 180 ppm in the 13C ssNMR spectrum for the synthesised zinc(II)-




Figure 42: 19F{1H, 13C} ssNMR spectrum of the synthesised zinc(II)-ciprofloxacin complex. 
Asterisks indicate spinning sidebands. 
 
Figure 43: 13C{1H} ssNMR spectrum of the synthesised zinc(II)-ciprofloxacin complex. Asterisks 
indicate spinning sidebands. 
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FTIR confirms the presence of a fluorinated compound, which can only be ciprofloxacin. The FTIR 
also suggests the coordination of ciprofloxacin to the zinc(II) ion. The characteristic carboxylic 
acid stretching vibration peaks for uncoordinated ciprofloxacin that are normally found between 
1722-1707 cm-1 are not observed for this complex and there is an emergence of two peaks; at  
1614 and 1379 cm-1 which are attributed to the O=C-O asymmetric and symmetric stretching 
vibrations, respectively110. Furthermore, a peak is observed at 624 cm-1 which is typical of an M-
O stretching vibration111, 112.   
However, the characterisation of the repeat experiment differed significantly from both the 
reported values and the theoretical values. Both the melting point and the elemental analysis 
are different to what was expected. The melting point range of the repeated compound is higher 
than the melting point range of the reported compound (282-284 ℃ versus 218-220 ℃ 40 
respectively). The elemental analysis also suggests that the repeated synthesis did not yield the 
expected product. The results of the elemental analysis found: C 47.16 %, H 5.15 % and N 9.54 
%. These values are far closer to the calculated values for a structure of the compound shown 
in figure 44; [Zn(H2O)2(cf-)(OH)]. The calculated elemental analysis for [Zn(H2O)2(cf-)(OH)] is: C 
45.50 %, H 4.94 % and N 9.36 %.  
 
Figure 44: proposed structure of the repeated synthesis of a zinc(II)-ciprofloxacin structure, 
based on elemental analysis of the compound. 
Once again, due to the poor solubility of the compound, attempts at crystallisation have been 
unsuccessful. Without an X-ray crystal structure, we cannot be certain that the zinc(II) ion is 




2.2 Other attempts at metallo-FQ complexation 
 
Many other attempts at synthesising metallo-fluoroquinolone complexes were undertaken and 
are summarised in table 14. The initial efforts to synthesise an iron(III)-ciprofloxacin complex 
were based on the method described by Saleh MD113, in which a 1:4 ratio of iron(III) chloride 
anhydrous and ciprofloxacin were used to create crystals of a 1:2 iron(III)-ciprofloxacin complex. 
This was unsuccessful in the repeats of this method, but inspired further investigation into the 
optimisation of the reaction conditions. Experiments with other iron(III) sources found that the 
iron(III) source has an important role in the formation of the iron(III)-ciprofloxacin complex.  
Previous attempts at the complexation of iron(III) and ciprofloxacin had used iron(III) chloride as 
the iron(III) source, these attempts had been unsuccessful under the same conditions as the 
successful iron(III) chloride hexahydrate synthesis.  
Table 14: summary of unsuccessful attempts at synthesis of metallo-fluoroquinolones.  
Reaction M:FQ ratio Metal source  Fluoroquinolone  
1:4 Iron(III) chloride anhydrous Ciprofloxacin  
1:4  Iron(III) acetylacetonate Ciprofloxacin  
1:2, 1:3, 1:4 Iron(III) chloride hexahydrate Ciprofloxacin  
1:1 Iron(III) nitrate nonahydrate Ciprofloxacin  
1:1, 1:2, 1:3, 1:4 Iron(III) chloride hexahydrate Nalidixic acid 
1:1, 1:2, 1:3, 1:4 Gallium(III) nitrate anhydrous Ciprofloxacin 
1:2 Sodium molybdate Ciprofloxacin  
1:2  Sodium tungstate Ciprofloxacin  
1:2 Ammonium vanadate Ciprofloxacin  
1:2 Terbium(III) chloride hexahydrate Ciprofloxacin  
 
2.3 Conclusions  
 
The complexation of iron(III) and ciprofloxacin is dependent on many factors. Firstly the ratio of 
iron(III) and ciprofloxacin, the optimum metal-to-ligand ratio at pH 2 is 1:1 however this does 
not yield a stoichiometric product. The pH plays an important role in the availability of the donor 
atoms in ciprofloxacin to coordinate to the iron(III) ion, as well as the solubility of the reactants. 
The literature available on the pKa values of ciprofloxacin species along with an investigation of 
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the UV/vis absorbance of the reaction solution at different pH values concludes that pH 2 is an 
ideal pH for complexation. The crystallisation technique is also imperative to the production of 
good quality crystals for analysis via X-ray crystallography, solvent vapor evaporation 
crystallization was the most favorable technique out of those set up with these reactions. By 
slowing down the crystallization process, the growth of better quality crystals occurred. Further 
investigation is required into the gel crystallization technique. Furthermore, the iron(III) source 
is a critical factor in the iron(III)-ciprofloxacin complexation. Some iron(III) sources did not yield 
an iron(III)-ciprofloxacin complexes, due to solubility issues or subsequent changes in pH. 
Iron(III) chloride hexahydrate yielded a 1:2 iron(III)-ciprofloxacin complex, however this complex 
included chloride anions coordinated to the iron(III) ion, which is not optimal. Iron(III) sulfate as 
an iron(III) source also yielded iron(III)-ciprofloxacin complexes, including a 1:1 iron(III)-
ciprofloxacin complex, which was not observed with the iron(III) chloride hexahydrate iron(III) 
source. The 1:1 and 1:2 iron(III)-ciprofloxacin sulfate complexes are positively and negatively 
charged, respectively, meaning that their formation is likely to be codependent. 
Other metallo-ciprofloxacin complexes are also feasible, with examples of bismuth(III) and 
zinc(II) complexes which have been synthesised from literature reported procedures discussed 
19, 40. 
2.4 Future work  
 
Further investigation into the gel layering crystallisation technique could provide a basis for 
forming other metallo-fluoroquinolone complexes. Other fluoroquinolones will have their own 
unique pKa profile and therefore gel layering could be the answer to crystallising the complexes 
which have so far been unsuccessful attempts. The gel layering crystallisation technique could 
also yield better quality crystals for more refined structures of the iron(III)-ciprofloxacin 
complexes. 
Crystallisation of zinc(II) and bismuth(III) compounds which have been discussed would allow for 




3. Ciprofloxacin Dimers  
3.1 Aims and objectives  
The overarching aim of this section of work was to synthesise novel dimeric ciprofloxacin 
compounds with potentially enhanced antimicrobial or anti-tumour properties over 
ciprofloxacin. This aim is based on literature research into the antimicrobial and anti-tumour 
properties of fluoroquinolone dimers. The objectives to achieve this aim were to research 
published examples of fluoroquinolone dimer compounds, to design a synthetic procedure and 
to characterise the products of the synthesis. The design, synthesis and characterisation of two 
compounds; an EDTA and a DTPA linked ciprofloxacin dimer was achieved. 
3.2 Introduction  
The ciprofloxacin dimers that have been synthesised as part of this section of work are 
comprised of two ciprofloxacin units connected with a linker (figure 45); in this case one used 
an ethylenediaminetetraacetic acid (EDTA) linker and the other a diethylenetriaminepentaacetic 
acid (DTPA) linker. The fluoroquinolone dimers were designed to be connected to the linker 
through the piperazinyl nitrogen. By linking the fluoroquinolones at this position, the ketone and 
carboxylic acid groups at the other end of the molecule is still able to coordinate to DNA gyrase, 
a critical part of the fluoroquinolone pharmacophore’s antimicrobial mechanism of action. The 
dimer compound is designed to be able to bridge between the coordination sites in the 
fluoroquinolone’s intracellular target; DNA gyrase, which is a dimer comprised of gyrA and 
gyrB48-51. By simultaneously targeting both fluoroquinolone target bi sites there could be 
enhanced antimicrobial effectiveness. 
 
Figure 45: generic structure of dimeric ciprofloxacin compounds comprised of two ciprofloxacin 
molecules connected by a linker. 
Overprescription of fluoroquinolone drugs due to their broad spectrum of antimicrobial activity 
has resulted in increasing resistance. Bacterial resistance to fluoroquinolones occurs in two 
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ways; a mutation at the fluoroquinolone binding site in DNA gyrase and mechanisms to reduce 
accumulation of fluoroquinolones intracellularly114.  
Fluoroquinolone resistance arising from mutations in DNA gyrase predominantly occur in the 
plasmid mediated quinolone resistance (PMQR) gene in gyrA in the form of a deletion or 
insertion mutation at amino acid 83. The mutation in PMQR causes a local conformational 
change at the 5’ terminus in gyrA quinolone resistance determining region (QRDR) and as a result 
a loss of enzyme-fluoroquinolone activity114-116. The mutation described in gyrA has been shown 
to give rise to resistance to quinolone drugs but not to unrelated compounds117, therefore 
making adaptations to ciprofloxacin could overcome resistance occurring through gyrA 
mutations.  
Bacterial resistance to fluoroquinolones also occurs though reduced intracellular 
fluoroquinolone accumulation. Increased active efflux of fluoroquinolone molecules by 
transmembrane proteins reduces the concentration of fluoroquinolone drugs in bacterial cells. 
However, even with increased activity of efflux proteins there are still low level concentrations 
of fluoroquinolone within bacterial cells due to binding to intracellular compounds and pH 
effects. Only fluoroquinolone zwitterions can be effluxed, but intracellular reactions can yield 
charged fluoroquinolone molecules in bacterial cells118. Fluoroquinolone dimer compounds 
possess more electronegative atoms per molecule than a fluoroquinolone molecule and 
therefore are more likely to form negatively charged ions or coordinate to compounds 
intracellularly. Therefore a fluoroquinolone dimer complex could accumulate higher 
intracellular concentrations than traditional fluoroquinolone drug molecules. A further 
mechanism of reducing intracellular fluoroquinolone accumulation is through the reduced 
expression of porin proteins. Fluoroquinolone molecules enter bacterial cells via passive 
diffusion through porins. Reduced expression of porins would result in less diffusion of 
fluoroquinolone drug molecules into bacterial cells114. Whilst porins would also be the primary 
transport mechanism for fluoroquinolone dimers, one molecule of a fluoroquinolone dimer 
contains twice the fluoroquinolone pharmacophores as a traditional fluoroquinolone drug and 
therefore has the potential to have increased antimicrobial properties at lower concentrations 
than monomeric fluoroquinolone drugs.  
Cancer is a multifactorial disease arising from uncontrolled cell growth and is a major public 
health concern globally119. Because fluoroquinolone drugs target DNA replication enzymes 
(DNA gyrase) to inhibit cell growth, their anti-tumour properties have been investigated. The 
intracellular target for fluoroquinolones is type II topoisomerases, both bacterial and human 
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DNA type II topoisomerases are classified as type II A. In bacteria type II A topoisomerase is 
DNA gyrase and topoisomerase IV and in humans it is made up of a topoisomerase II α and β 
dimer132 (figure 46).   
 
Figure 46: schematic diagram showing the various types of DNA type II topoisomerases132. 
Mammalian topoisomerase II has similar functions to bacterial topoisomerase II in DNA 
replication and transcription. Mammalian topoisomerase II is already the intracellular target for 
the anti-tumour drugs doxorubicin and mitoxantrone, shown in figure 47. Doxorubicin and 
mitoxantrone are examples of topoisomerase II poisons because they cause damage to the 
topoisomerase II-DNA complex. Other anti-tumour drugs which target topoisomerase II do so 




Figure 47: structures of two anti-tumour drugs which target mammalian topoisomerase II. Top: 
doxorubicin. Bottom: mitoxantrone. 
Ciprofloxacin has demonstrated anti-tumour properties against bladder and prostate cancerous 
cells110, 122,133. Often, complications arising from cancer treatments are bacterial infections as a 
result of a weakened immune system; a side-effect of anti-tumour treatments. As such, an 
antimicrobial anti-tumour drug could be a significant advancement in anti-tumour therapy. 
Furthermore, fluoroquinolone drugs tend to have significantly milder side-effects relative to 
current anti-tumour drugs.  
Dimer fluoroquinolone complexes with modifications at either the carboxylic or piperazinyl 
groups may display greater anti-tumour properties as they have reduced zwitterionic 
character123, which improves the cellular internalisation efficiency by increasing surface-cell 
interactions120. There are a few literature examples of fluoroquinolone dimer compounds which 
have been shown to have increased anti-tumour activity over the fluoroquinolone monomers, 






Figure 48: reported structures of fluoroquinolone dimers with increased anti-tumour properties 
in comparison to their fluoroquinolone monomers. Top: ciprofloxacin dimer with 
CH2OCO(CH2)14COOCH2 linker62. Middle: ciprofloxacin dimer with (CH2)14 linker62. Bottom: 
modified (ethyl group added to piperazinyl group) ciprofloxacin dimer with linker in the C3 
position63. 
A literature search for “fluoroquinolone dimer” using SciFinder124 returned 80 published 
materials. Of these 80 results, it was found that only four of the papers contained structures of 
fluoroquinolone dimers linked at the R2 position shown in figure 49. Table 15 summarises the 
currently published fluoroquinolone dimer molecules and whether they possess antimicrobial 




























Table 15: summary of current literature on fluoroquinolone dimer molecules and their 
antimicrobial/ anti-tumour properties.  
Fluoroquinolone Linker Antimicrobial  Anti-tumour Reference  
Ciprofloxacin (CH2)8  < < 62 
Ciprofloxacin (CH2)10 = < 62 
Ciprofloxacin (CH2)12  = < 62 
Ciprofloxacin (CH2)13 = < 62 
Ciprofloxacin (CH2)14  < > 62 
Ciprofloxacin (CH2)16 < < 62 
Ciprofloxacin CH2OCO(CH2)8COOCH2 < < 62 
Ciprofloxacin CH2OCO(CH2)10COOCH2 = = 62 
Ciprofloxacin CH2OCO(CH2)12COOCH2 = = 62 
Ciprofloxacin CH2OCO(CH2)13COOCH2 = = 62 
Ciprofloxacin CH2OCO(CH2)14COOCH2 = > 62 
Ciprofloxacin CH2OCO(CH2)16COOCH2 < = 62 
Gatifloxacin  CH2CH2 NT NT 125 
Ciprofloxacin CH2CHCHCH2 > NT 54, 56 
Ciprofloxacin m-(CH2)2(C6H4) < NT 54, 56 
Ciprofloxacin p-(CH2)2(C6H4) = NT 54, 56 
Ciprofloxacin CH2 (2,6-C5H3N) CH2 = NT 54, 56 
Levofloxacin (CH2)5 < < 62 
Levofloxacin (CH2)6 = = 62 
Levofloxacin (CH2)8 = = 62 
Levofloxacin (CH2)9 = = 62 
Levofloxacin (CH2)10 = = 62 
Levofloxacin (CH2)12 < < 62 
Norfloxacin  CH2CHCHCH2 = NT 54, 56 
Norfloxacin  p-(CH2)2(C6H4) < NT 54, 56 
NT: not tested, > : greater activity than fluoroquinolone monomer, = : activity is the same as 
fluoroquinolone monomer, < : activity is lower than fluoroquinolone monomer, m- : meta, p- : 
para.  
The results of the literature search highlight that there is potential for further research to be 




3.3 Ciprofloxacin methyl ester  
 
The fluoroquinolone starting reagent for the synthesis of both the EDTA-ciprofloxacin and DTPA-
ciprofloxacin dimers is ciprofloxacin methyl ester. Ciprofloxacin methyl ester is used in the dimer 
synthesise in order to protect the carboxylic acid group in ciprofloxacin, to selectively bond the 
linker compound to the ciprofloxacin molecules to yield the dimer compound. The synthesis for 
ciprofloxacin methyl ester was completed according to scheme 1.  
Scheme 1 
 
Evidence for the successful synthesis of ciprofloxacin methyl ester is best observed in the 1H 
NMR, which shows the addition of a peak associated with the added methyl group in comparison 
to the ciprofloxacin 1H NMR spectrum  This is similarly observed in the reported literature 
synthesis of ciprofloxacin methyl ester, in which the same NMR shifts are reported across 1H, 13C 
and 19F NMR. Furthermore, the literature procedure followed reported a positive ESI mass spec 
peak of m/z 346, which was also observed with this complex and attributed to being 
C18H21FN3O3. The FTIR and melting point values for the synthesised ciprofloxacin methyl ester 
compound are also consistent with the literature values, meaning that the synthesised 
compound was suitable to be used as a starting material in the synthesis of ciprofloxacin dimer 
compounds126.  
3.4 EDTA-ciprofloxacin dimer 
 
An EDTA linker was chosen as EDTA has been shown to demonstrate broad-spectrum 
antimicrobial properties and therefore could further enhance the antimicrobial properties of the 
compound 127, 128. EDTA’s antimicrobial properties arise from its ability to chelate inorganic 
components that bacterial cells rely on for survival 129. EDTA’s chelating abilities also present an 
opportunity to create metallo-dimer complexes, with potentially up to three chelation sites in 
the dimeric compound, to continue from the research on metallo-fluoroquinolone complexes. 
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A structure search for the proposed EDTA-linked ciprofloxacin dimer was undertaken using 
SciFinder124, which returned one pre-existing publication of the structure. The single search 
result was an international patent for “dual-sensitizer-containing luminescent compounds, 
conjugates, and uses thereof” whereby the EDTA-ciprofloxacin dimer was synthesised by 
reacting a two fold excess of ciprofloxacin with EDTA, for use as a lanthanide chelating probe for 
use in biological assays130. It is suggested in the afore mentioned patent that solvation of the 
EDTA-ciprofloxacin dimer in either water or methanol affects the intramolecular interactions of 
the molecule as shown in figure 50. Nowhere in the patent describe is any mention of potential 
antibiotic, antimicrobial or anti-tumour properties.  
 
Figure 50: proposed changes in stacking of EDTA-ciprofloxacin molecules as a result of different 
solvents130. 
The overall synthetic route taken to form the ETDA-ciprofloxacin dimer is shown in figure 51 and 




Figure 51: reaction scheme for the synthesis of the ciprofloxacin EDTA dimer sodium salt. 
The sodium salt of the product of the synthesis outlined in figure 53 is very hygroscopic, as 
shown by the water molecules included in the formula determined by elemental analysis 
(C44H44F2N8O12Na4.7H2O). It is unsurprising that the EDTA-ciprofloxacin dimer is hygroscopic 
given that it contains four carboxylate groups.  
In the first stage of the synthesis of the EDTA-ciprofloxacin dimer, ciprofloxacin methyl-ester is 
reacted with EDTA dianhydride. It is important that it is EDTA dianhydride in order to selectively 
add the fluoroquinolone to either end of the EDTA molecule. The methyl protecting groups in 
the EDTA-ciprofloxacin methyl ester compound are then removed using sodium hydroxide, 




High performance liquid chromatography (HPLC) of the EDTA-ciprofloxacin dimer sodium salt 
showed significant changes in the retention time in comparison to ciprofloxacin (figure 52). A 
longer retention time for the EDTA-ciprofloxacin dimer is what would be expected due to the 
introduction of more polar groups through the addition of the EDTA linker and also because the 
dimer is a significantly larger molecule than ciprofloxacin.  
 
Figure 52: HPLC graphs for ciprofloxacin (left) and EDTA-ciprofloxacin dimer (right). 
The NMR spectra for the EDTA-ciprofloxacin compound indicate that the structure has C2 
symmetry. The symmetry of the EDTA-ciprofloxacin compound is demonstrated by the single 
peak found in the hydrogen-uncoupled fluorine NMR spectrum, suggesting that the two fluorine 
atoms found in the proposed structure of the EDTA-ciprofloxacin structure have equivalent 




Figure 53: 19F{1H} NMR of EDTA-ciprofloxacin sodium salt, showing a single peak at -124.23 ppm 
with the zoomed in image of the peak in the top left. 
The single peak in the 19F{1H} NMR appears at -124.23 ppm which is similar to the chemical shift 
obtained for the ciprofloxacin methyl ester reagent used (-123.42 ppm), with the slight 
differences being accounted for by the different solvents used to record the spectra as a result 
of the different solubilities of the compounds. The spectra 19F{1H} NMR spectra for the EDTA-
ciprofloxacin dimer sodium salt and ciprofloxacin methyl ester are shown in figure 54.  
 
Figure 54: 19F{1H} NMR spectra for ciprofloxacin methyl ester (top) in chloroform-d, and the 
EDTA-ciprofloxacin dimer sodium salt (bottom) in DMSO-d6/sodium hydroxide. 
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Because of the poor solubility of the EDTA-ciprofloxacin dimer compound, the NMR spectra for 
this compound have been recorded in DMSO-d6 with dilute sodium hydroxide added. An NMR 
of sodium hydroxide in DMSO-d6 is shown in figure 55 in order to confirm that the signal at 2.54 
ppm is due to the hydroxide ions in solution.  
 
Figure 55: 1H NMR of sodium hydroxide and acetone in DMSO, with the corresponding peaks 
labelled. 
A 1H-1H correlation spectrum (COSY) was recorded in order to assist in assigning the signals in 
the 1H NMR spectrum (figure 60). The chemical shift assignments for the 1H NMR spectrum and 
the coupling found in the 1H-1H COSY spectrum for the EDTA-ciprofloxacin dimer sodium salt are 
summarised in table 19. The COSY confirmed the assignment of the signals at 0.91 and 1.17 ppm 
being attributable to the 4 cyclopropane protons labelled as 75 and 76 (figure 56) due to the 
coupling of both of these signals to the signal attributed to the single proton labelled 74 (3.40 
ppm) in the cyclopropane ring. However, the COSY did not allow for differentiation between the 
signals at 0.91 and 1.17 ppm and therefore the protons labelled 75 and 76. The COSY spectrum 
also confirmed the assignment of the signal at 3.15 ppm to be attributable to the four equivalent 
protons labelled 78 and 79, and the signal at 3.57 ppm to be attributable to the four equivalent 
protons labelled 80 and 81. The equivalency of the protons labelled 78/79 and 80/81 shown by 
the single peaks in the 1H and COSY NMR spectra further demonstrates the symmetry present 
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in the EDTA-ciprofloxacin dimer compound. The double doublet attributed to the proton 
labelled 5 in figure 56 does not show coupling in the COSY spectrum because it is split by fluorine.  
 
Figure 56: numbered structure of the EDTA-ciprofloxacin dimer sodium salt. 
 
 
Figure 57: 1H-1H COSY spectrum for the EDTA-ciprofloxacin dimer sodium salt in sodium 






Table 16: summary of the EDTA-ciprofloxacin dimer sodium salt 1H NMR chemical shifts and 
associated data (integration and multiplicity) as well as any 1H-1H coupling observed in the 
COSY NMR spectrum recorded in sodium hydroxide and DMSO-d6.  
Label  1H Chemical 
shift / ppm 




5 7.59 1 dd CH - 3JH,F = 13.3, 2.6 
8 3.57 4 d CH2 3.15 3JH,H = 23.1 
9 3.15 4 d CH2 3.57 3JH,H = 2.9 
14 2.92 4 s CH2 - - 
15 3.15 4 d CH2 3.57 3JH,H = 2.9 
16 3.57 4 d CH2 3.15 3JH,H = 23.1 
17 7.37-7.19 1 m CH - - 
19 3.40 1 m CH 0.91, 1.17 - 
20 0.91, 1.17 2 m CH2 0.91, 1.17, 3.40 1JH,H = 6.0 
21 0.91, 1.17 2 m CH2 0.91, 1.17, 3.40 1JH,H = 6.0 
22 8.35 1 s CH - - 
 
The EDTA-ciprofloxacin dimer sodium salt was also characterised by its melting point which was 
found to be 195-196 ℃, mass spectrometry and FTIR. ESI negative mode mass spectrometry 
found two peaks for the EDTA-ciprofloxacin dimer. A peak at m/z 917.3258 is attributed to the 
protonated compound rather that the sodium salt, and a peak at m/z 939.3080 is attributed to 
the singly deprotonated sodium salt. The FTIR for the EDTA-ciprofloxacin compound shows the 
same characteristic peaks as the FTIR of ciprofloxacin.  
The EDTA-ciprofloxacin dimer sodium salt has several donor atoms which could in theory 
coordinate to a metal ion. A Job’s plot to analyse the possible coordination of the EDTA-
ciprofloxacin dimer sodium salt to iron(III) was attempted, however over a range of molar 
fractions of the EDTA-ciprofloxacin dimer sodium salt there was no absorbance in the UV spectra 
that would be consistent with coordination to a metal ion. This problem arose because of the 
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poor solubility of the EDTA-ciprofloxacin dimer sodium salt- as it has only been found to be 
soluble in weakly basic conditions it is likely that an iron(III)-hydroxide species formed, the 
complexation of which outcompeted the formation of an EDTA-ciprofloxacin dimer-iron(III) 
complex. Further investigation into the coordination of the EDTA-ciprofloxacin dimer sodium 
salt to metal ions could yield interesting complexes with medicinal and bioinorganic properties.   
3.5 DTPA-ciprofloxacin dimer 
 
DTPA is a commercial chelator and as such has demonstrated antimicrobial properties through 
the chelation of iron, an essential ion for bacteria122.  A dimer which incorporated DTPA as a 
linker molecule could therefore have enhanced antimicrobial properties.  
A structure search for an EDTA linked ciprofloxacin dimer using SciFinder124 found one result; a 
patent previously discussed in the EDTA-ciprofloxacin dimer section130. Similarly to the EDTA-
ciprofloxacin dimer, within this patent it suggests that the solvent affects to stacking of the 
DTPA-ciprofloxacin molecule as summarised in figure 58. The proposed application of the DTPA-
ciprofloxacin molecule in this patent is as a lanthanide chelating probe for use in biological 
assays and indeed the potential antimicrobial, antibacterial or anti-tumour applications have not 

















































Figure 58: DTPA-ciprofloxacin dimer stacking interaction as a result of different solvents81. 
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The synthesis of the DTPA-ciprofloxacin dimer sodium salt is summarised in figure 59. The 
synthesis of the DTPA-ciprofloxacin methyl ester dimer used ciprofloxacin methyl ester 
(synthesis summarised in equation 6) and DTPA dianhydride. It is important that the DTPA is the 
dianhydride in order to yield the desired structural isomer. The DTPA-ciprofloxacin methyl ester 
dimer was then deprotected using sodium hydroxide in order to yield the DTPA-ciprofloxacin 
dimer sodium salt.  
 
Figure 59: reaction scheme for the synthesis of the ciprofloxacin DTPA dimer sodium salt. 
Elemental analysis suggests the formula of the DTPA-ciprofloxacin dimer to be a sodium salt 
with traces of sodium chloride and water; C48H50F2N9O14Na5.2NaCl.3H2O. The sodium chloride 
salt impurity arises from the sodium hydroxide added to deprotect the DTPA-ciprofloxacin 
methyl ester dimer and the hydrochloric acid which was added to adjust the pH. Most of the 
93 
 
sodium chloride salt was removed by washing the precipitate with water, but after three washes 
there is evidently still sodium chloride present. The water molecules in the product are 
unsurprising as the DTPA-ciprofloxacin dimer is hygroscopic.  
19F NMR spectroscopy indicates that the DTPA-ciprofloxacin dimer sodium salt has C2 symmetry 
as observed in the EDTA-ciprofloxacin dimer because there is only a single resonance associated 
with the two fluorine atoms in the molecule, suggesting that they are in equivalent chemical 
environments. The 19F{1H} NMR spectrum of the DTPA-ciprofloxacin dimer sodium salt is shown 
in figure 60.  
 
Figure 60: 19F{1H} NMR spectrum of the DTPA-ciprofloxacin dimer sodium salt with an expanded 
image showing that there is only a singlet peak. 
The 19F{1H} NMR spectrum of the DTPA-ciprofloxacin dimer sodium salt also shows that the 
chemical shift of the DTPA-ciprofloxacin dimer sodium salt fluorine atoms is the same as the 




Figure 61: stacked 19F{1H} NMR spectra of the EDTA-ciprofloxacin dimer sodium salt (top) and 
the DTPA-ciprofloxacin dimer sodium salt (bottom) showing that they contain a single peak at -
124.23 ppm. 
A 1H-1H correlation spectrum (COSY) was recorded in order to assist in assigning the signals in 
the 1H NMR spectrum (figure 66). The chemical shift assignments for the 1H NMR spectrum and 
the coupling found in the 1H-1H COSY spectrum for the EDTA-ciprofloxacin dimer sodium salt are 
summarised in table 17.  
Using the COSY spectrum, the signals at 2.93 and 3.44 ppm were confirmed to be attributed to 
the two sets of equivalent protons in the piperazinyl groups labelled 128, 129, 148 and 149 in 
figure 62. The single resonance assigned to protons 128 and 148 at 2.93 ppm further confirms 
the symmetry of the DTPA-ciprofloxacin dimer molecule, similarly with the single resonance at 
3.44 ppm which is attributed to the equivalent protons labelled 129 and 149. The COSY spectrum 
further confirms the assignment of the peaks at 2.93 and 3.44 ppm to be the piperazinyl protons 
as these signals couple to one another. The COSY confirmed the assignment of the signals at 
1.09 and 1.14 ppm being attributable to the 4 cyclopropane protons labelled as 144 and 145 due 
to the coupling of both of these signals to the signal attributed to the single proton labelled 143 
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(3.73 ppm) in the cyclopropane ring. However, the COSY did not allow for differentiation 
between the signals at 1.09 and 1.14 ppm and the protons labelled 144 and 145.  
 
Figure 62: numbered structure of the DTPA-ciprofloxacin dimer sodium salt. 
 









Table 17: summary of the DTPA-ciprofloxacin dimer sodium salt 1H NMR chemical shifts and 
associated data (integration and multiplicity) as well as any 1H-1H coupling observed in the 
COSY NMR spectrum recorded in DMSO-d6 and sodium hydroxide.  
Label  1H Chemical 
shift/ ppm 





8 2.94 4 d CH2 3.44 3JH,H = 8.1 
9 3.45 4 dd CH2 2.94, 3.65 3JH,H = 14.7, 
6.8 
11 3.65 2 d CH2 3.45 3JH,H = 5.1 
12 2.10 2 s CH2 - - 
14 2.86 2 s CH2 - - 
18 3.45 4 dd CH2 2.94, 3.65 3JH,H = 14.7, 
6.8 
19 2.94 4 d CH2 3.45 3JH,H = 8.1 
22 3.72 1 m CH 1.10, 1.27 3JH,H = 3.6 
23 1.10, 1.27 2 m CH2 1.10, 1.27, 
3.72 
- 
24 1.10, 1.27 2 m CH2 1.10, 1.27, 
3.72 
- 
25 7.81-7.69 1 m CH - - 
 
The melting point for the DTPA-ciprofloxacin dimer sodium salt (205-206 ℃) is higher than the 
melting point for the EDTA-ciprofloxacin dimer sodium salt (195-196 ℃), which is what would 
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be expected because of the additional acid groups in the DTPA linker compared to the EDTA 
linker, which means that there are more electronegative atoms capable of intermolecular 
interactions. Additionally, the DTPA-ciprofloxacin dimer is larger in general that the EDTA-
ciprofloxacin dimer, again meaning that there are more intermolecular interactions in the DTPA-
dimer than the EDTA-dimer and thus the DTPA-dimer has a higher melting point.  
Attempts at gaining mass spectrometry data for the DTPA-ciprofloxacin dimer were unsuccessful 
because of the poor solubility of the DTPA-ciprofloxacin dimer. However, negative ESI mass 
spectrometry of the DTPA-ciprofloxacin methyl ester dimer which is much more soluble found 
a peak at m/z 1046.4034 in methanol, which corresponds to C50H58F2N9O14 (m/z 1046.4077, 0.7 
ppm error).  
The FTIR spectrum for the DTPA-ciprofloxacin dimer sodium salt is consistent with what would 
be expected of a ciprofloxacin containing compound, with many of the peaks being attributable 
to both ciprofloxacin and the DTPA linker, such as the C-H stretching at 2982 cm-1, C=O stretching 
at 1709 cm-1 and the O-H bending at 1408 cm-1 from a carboxylic acid group. The presence of 
the O-H bending peak also signifies that some of the molecules in the compound are contain 
carboxylic acid groups rather than the salt forming carboxylate groups.  
The characterisation data presented shows that a DTPA-ciprofloxacin dimer has been 
synthesised. The synthesis of a DTPA-linked ciprofloxacin dimer provides a foundation for 
further research into the biological applications, such as for antimicrobial or anti-tumour agents, 
of linked ciprofloxacin dimers.  
3.6 Conclusions 
 
Two dimeric ciprofloxacin molecules have been designed, synthesised and characterised. The 
synthetic routes to form both an EDTA and a DTPA linked ciprofloxacin dimer have been 
outlined. Techniques used to characterise the EDTA and DTPA-ciprofloxacin dimers include 
melting point, FTIR, 1H NMR, 13C NMR, 19F NMR, 1H-1H COSY NMR, HPLC and mass spectrometry. 
Characterisation of both the EDTA and DTPA ciprofloxacin dimers show that both are 
hygroscopic and should be handled/ stored as such. Furthermore, based of fluorine NMR 
spectroscopic investigations it has been demonstrated that both the EDTA and DTPA 
ciprofloxacin dimers exhibit C2 symmetry. Further investigation into the applications of both the 
synthetic routes to form a ciprofloxacin dimer and the properties of the ciprofloxacin dimers 




3.7 Future Work  
 
Now that there is a synthetic route to create EDTA and DTPA linked ciprofloxacin dimers, these 
compounds should have their antimicrobial and anti-tumour activities examined in order to 
determine the applications of these compounds in medicines and bioinorganic chemistry.  
Furthermore, the synthesise outlined could be applied to create other dimeric fluoroquinolone 
compounds, both with different fluoroquinolone and with linker molecules.  
Further investigation into the coordination of the described ciprofloxacin dimer complexes to 
metal ions should be undertaken. In order to do this, the solubility issues of the dimeric 
compounds have to be addressed. Coordination of the dimeric ciprofloxacin compounds could 
further enhance their antimicrobial properties based on the same reasoning as metallo-
ciprofloxacin complexes.  
Beyond the scope of this project, the development of a synthesis for asymmetric 
fluoroquinolone dimers could have further increased antimicrobial and/or anti-tumour activity 
over the respective fluoroquinolone compounds56. If there is resistance to one of the 
fluoroquinolone pharmacophores in the molecule the compound may still show 
antimicrobial/anti-tumour activity through the other fluoroquinolone pharmacophore which 









4. Overall summary, conclusions and future work  
 
There is a need for innovation to produce new antimicrobial agents in order to combat the rise 
in antimicrobial resistance. Ciprofloxacin is a frequently prescribed fluoroquinolone antibiotic 
drug, however, increasing antimicrobial resistance is compromising its efficacy. Presented is an 
investigation into two approaches to modify the structure of ciprofloxacin in order to promote 
its antimicrobial activity. The two approaches presented are the formation of metallo-
ciprofloxacin complexes and the synthesis of linked dimeric ciprofloxacin molecules.  
4.1 Metallo-ciprofloxacin complexes  
 
Coordination of ciprofloxacin to metal ions may enhance the antimicrobial properties of 
ciprofloxacin through the additional biological effects of the metal ions whether that be in vivo 
transportation for biologically available metal ions or antimicrobial properties.  There are 
literature examples of metallo-fluoroquinolone complexes which have had increased 
antimicrobial properties over the respective fluoroquinolone on its own.  
Preliminary experiments investigated the pH dependence of the complexation of iron(III) and 
found that pH 2 is a preferential to pH 3 and that a iron(III)-to-ciprofloxacin ratio of 1:1 is 
optimum for iron(III)-ciprofloxacin complexation. Various crystallisation techniques were used, 
with the most successful being vapour diffusion. Presented are three novel fluoroquinolone 
complexes: a 1:2 iron(III)-ciprofloxacin complex, a 1:1 and 1:2 iron(III)-ciprofloxacin salt and a 
1:1 zinc(II)-ciprofloxacin complex. These complexes have been characterised using a range of 
techniques including X-ray crystallography, XRF, FTIR, melting point and elemental analysis.  
The antimicrobial properties of both the iron(III)-ciprofloxacin complexes as well as the zinc(II) 
and bismuth(III)-ciprofloxacin complexes should be investigated in order to evaluate their 
effectiveness as antimicrobial agents. To gain further structural information for the zinc(II) and 
bismuth(III) complexes that have been synthesised, good quality crystals should be grown in 
order to obtain crystallographic information. Furthermore, gel crystallisation techniques could 
lead to better crystals of metallo-fluoroquinolone complexes. Future work into metallo-
fluoroquinolone complexes should employ similar preliminary experiments in order to 
determine reaction conditions such as the ratio and pH required to form other metallo-




4.2 Linked dimeric ciprofloxacin compounds  
 
The fluoroquinolone intracellular target molecule; DNA gyrase, exists as a dimer. A linked 
fluoroquinolone dimer drug could bridge between the two binding sites in DNA gyrase. The few 
literature examples which are discussed suggest that dimeric fluoroquinolone compounds could 
have enhanced antimicrobial properties and may even possess anti-tumour properties.  
As part of the research that has been presented, two linked ciprofloxacin dimers have been 
synthesised; an EDTA-ciprofloxacin dimer and a DTPA-ciprofloxacin dimer. The EDTA and DTPA 
linkers were chosen because they have been found to possess antimicrobial properties on their 
own due to their ability to chelate iron(III), an essential ion for bacteria. The synthetic route to 
form both the EDTA- and DTPA-ciprofloxacin dimers have been summarised as well as the 
characterisations for each compound. The dimer compounds which have been synthesised have 
been characterised using NMR, mass spectrometry, elemental analysis, HPLC, FTIR and melting 
point. The elemental analysis found that both the EDTA and DTPA-ciprofloxacin dimers were 
isolated as sodium salts. NMR spectroscopy confirmed that both the compounds have C2 
symmetry.   
The next steps in researching linked ciprofloxacin compounds should be to test the antimicrobial 
and anti-tumour properties of the EDTA and DTPA-ciprofloxacin dimer sodium salt compounds, 
now that these compounds have been isolated and characterised. An investigation into the 
biological properties of asymmetric linked fluoroquinolone dimer compounds could find further 
improved antimicrobial or anti-tumour properties because if resistance occurs against one of 
the fluoroquinolone pharmacophores in the compound, the other fluoroquinolone in the 






5.1 General Remarks 
  
5.1.1 Materials  
All chemicals were obtained from commercial suppliers: Alfa Aesar, Acros, Merck and Sigma 
Aldrich. 
5.1.2 Instruments  
1H, 13C and COSY NMR spectra recorded on a Jeol ECS 400 at 400 MHz for 1H and 100 MHz for 
13C at ambient temperature, unless otherwise stated. 13C and 19F solid state NMR spectra 
recorded on a Bruker AVIIIHD 400 MHz at ambient temperature by Mr. C. Goult. NMR data is 
reported as following: chemical shift (multiplicity, coupling constants, assignment, number of 
protons). Chemical shifts are reported relative to residual solvent peaks to the nearest 0.01 ppm 
for 1H spectra and 0.1 ppm for 13C spectra. Multiplicity is reported as s=singlet, d=doublet, 
t=triplet, q=quartet, m=multiplet, br=broad. Coupling constants (J) are given in Hz and quoted 
to the nearest 0.5 Hz. All NMR spectra have been processed using MestReNova analysis 
software.  
High resolution ESI mass spectra were recorded on a Bruker microTOF electrospray mass 
spectrometer by Mr. K. Heaton.  
Thin layer chromatography (TLC) used Merck silica gel 60 F253 aluminium-backed plates using 
specified solvent systems and visualised under an ultraviolet lamp. 
 X-ray crystals structures were obtained from an Oxford Diffraction SuperNova equipped with a 
4-circle goniometer and dual copper and molybdenum micro-focus X-ray sources, samples were 
run by Dr Adrian Whitwood and images viewed on Crystal Maker software.  
pH values were measured using a Mettler Toledo InLab pH electrode at ambient temperature, 
unless otherwise stated.  
Fourier transform infrared (FT-IR) spectroscopy was obtained on a PerkinElmer Spectrum Two 
FT-IR spectrometer. Spectra are reported as: absorption cm-1 (appearance, group, compound 
class). Appearance is reported as: s=strong, m=medium, w=weak, br=broad.  
Melting points were measured using Stuart Scientific Melting Point Apparatus SMP3.  
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5.2 Methods  
5.2.1 Job’s Plot  
pH 2  
A stock solution of ciprofloxacin (1.81 x10-3 mol dm-3) was made up from ciprofloxacin 
(C17H18FN3O3, 15 mg, 0.045 mmol) in hydrochloric acid (25 mL, 0.1 M). A stock solution of iron(III) 
(1.81 x10-3 mol dm-3) was made up from iron(III) trichloride (FeCl3, 6.0 mg, 0.037 mmol) in 
hydrochloric acid (25 mL, 0.1 M). The stock solutions were used to make samples of varying 
molar ratio of iron and ciprofloxacin between 0.00 and 1.00 in 0.1 increments. UV-vis 
spectroscopy was used to analyse the samples.  
pH 3  
Hydrochloric acid (1 M) was added dropwise to deionised water (20 mL), whilst measuring the 
pH using a pH probe. Hydrochloric acid (0.5 mL, 1 M) was added to deionised water (20 mL) to 
make a pH 3 solution. This solution was used to make separate equimolar stock solutions (1.81 
x10-3 mol dm-3) of ciprofloxacin and iron(III) trichloride. The stock solutions were used to make 
samples of varying molar ratio of iron(III) and ciprofloxacin between 0.00 and 1.00 in 0.1 
increments. UV-vis spectroscopy was used to analyse the samples.  
5.2.2 Metallo-fluoroquinolone precursors 
5.2.2.1 Ciprofloxacin Sodium Salt  
 
C17H18FN3O3Na 
Mr : 354.1224 g mol-1 
 
Ciprofloxacin (680 mg, 2.1 mmol) was added to deionised water (3 mL). A solution of sodium 
hydroxide pellets (NaOH, 80 mg, 2.0 mmol) in deionised water (0.3 mL) was added to the 
ciprofloxacin solution and stirred for 30 minutes, a white precipitate formed. The solution was 
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filtered into a round bottomed flask and concentrated, leaving a crystalline yellow precipitate 
(1-21, 553.4 mg, 1.6 mmol, 94 % yield).  
m.p: 321-323 ℃ (lit131: 325 ℃).   
IR  2926 cm-1 (m, C-H stretching, alkane), 1628 cm-1 (m, O=C-O asymmetric stretching),  1625 cm-
1 (m, C=C stretching, conjugated alkene), 1370 cm-1 (m, O=C-O symmetric stretching), 1263 cm-1 
(s, C-F stretching), 882 cm-1 (s, C=C bending, alkene).  
1H NMR (400 MHz, D2O) δH 8.32 (s, 1H, C=H3), 7.59 (d, 3JH,F = 13.5 Hz, Ar-H19, 1H), 7.30 (d, 4JH,F = 
7.3 Hz, Ar-H9, 1H), 3.38 (tt, 3JH,H = 7.4, 4.0 Hz, H5, 1H), 3.05 (t, 3JH,H = 6.4 Hz, H12/16, 4H), 2.88 (t, 
3JH,H = 6.4 Hz, H13/15, 4H), 1.18 (m, H6/7, 2H), 0.96 – 0.87 (m, H6/7, 2H).  
13C NMR (101 MHz, D2O) δC 175.4 (s, C21) , 172.5 (s, C1-OOH), 154.4 (d, 1JC,F = 209.6 Hz ,C17), 
151.9 (s, C3), 144.4 (d, 2JC,F = 10.6 Hz, C10), 138.4 (s, C9), 122.0 (d, 3JC,F = 7.3 Hz, C20), 111.3 (d, 
2JC,F = 22.9, 12.3 Hz, C19), 106.4 (s, C8), 50.6 (s, C12/16), 43.7 (s, C13/15), 34.7 (s, C5), 7.4 (s, 
C6/7).  
19F NMR {1H}(376 MHz, D2O) δ -124.26 (s, F18). 
MS (ESI+, CH3OH): found m/z 354.1231 (calc. for C17H18FN3NaO3 = m/z 354.1224, 1.4 ppm error). 
Data consistent with literature values131 
5.2.2.2 Bismuth Oxynitrate (BiONO3, Mr: 286.9834 g mol-1)Bismuth(III) nitrate pentahydrate 
(Bi(NO3)3.5H2O, 1.20 g, 2.5 mmol) was added to deionised water (15 mL) with vigorous stirring 
for 30 minutes, followed by sonication for 15 minutes. The pH was adjusted to 7 using ammonia 
solution and the mixture was then sonicated for a further 15 minutes. The solution was heated 
at 180 ℃ for 30 minutes. The solution was vacuum filtered, and the precipitate washed three 
times with deionised water and left to dry. The product was a white powder (0.7048 g, 2.6 mmol, 
81 % yield).  
The product had poor solubility, limiting characterisation techniques to IR and melting point.  
m.p: >400 ℃ (limit of the machine).  
IR 1511 cm-1 (w, N-O symmetric stretching), 1322 cm-1 (s, N-O asymmetric stretching).  





5.2.3 Metallo-fluoroquinolone synthesise 
 




Mr: 941.06 g mol-1 
Ciprofloxacin (C17H18FN3O3, 25 mg, 0.1 mmol) was dissolved in hydrochloric acid (0.8 mL, 0.1 M) 
at 50 ℃. Iron(III) chloride hexahydrate (FeCl3.6H2O, 21 mg, 0.1 mmol) was added to the 
ciprofloxacin solution, and stirred at room temperature for four hours. The solution was then 
divided into 0.5 mL aliquots and set up for vapour diffusion crystallisation with acetone and left 
undisturbed for one week (see section 2.3 crystallisation methods). After one week, small red 
square-shaped crystals formed (8.2 mg,  8.7x10-3 mmol, 23 %).  
m.p: 220-221 ℃.  
IR: 1610 cm-1 (m, O=C-O asymmetric stretching), 1454 cm-1 (m, C-H bending, alkane), 1376 cm-1 









Mr: 1463.15 g mol-1 
Ciprofloxacin (C17H18FN3O3, 50 mg, 0.2 mmol) was dissolved in sulfuric acid (0.8 mL, 0.01 M) at 
37 ℃. Iron(III) sulfate (Fe2(SO4)3, 30 mg, 0.08 mmol) was added to the ciprofloxacin solution, and 
stirred at room temperature for three hours. The solution was then divided into 0.5 mL aliquots 
and set up for vapour diffusion crystallisation with acetone and left undisturbed for one week 
(see section 5.2.5 crystallisation methods). After one week, small red square-shaped crystals 
formed. 
m.p: 352-356 ℃.  
IR: 1610 cm-1 (m, O=C-O asymmetric stretching), 1465 cm-1 (m, O=C-O symmetric stretching), 
1385 cm-1 (m, S=O asymmetric stretching), 1270 cm-1 (s, C-F stretching), 599 cm-1 (m, Fe(III)-O 
stretching), 1183 cm-1 (m, S=O symmetric stretching). 
5.2.3.3  1:3 Bismuth(III)- ciprofloxacin: [Bi(ciprofloxacin)3(H2O)2]  
 
Bismuth oxynitrate (BiONO3, 50 mg, 0.02 mmol) was dissolved in hydrochloric acid (1 mL, 0.1 
M). Separately, ciprofloxacin (C17H18FN3O3, 290 mg, 0.88 mmol) was dissolved in hydrochloric 
acid (1.5 mL, 0.1 M). The two solutions were combined, producing a white precipitate. The 
resulting solution was filtered into a round bottomed flask and the filtrate was heated to 85 ℃ 
for six hours. Three drops of ammonia solution were added every hour in order to maintain the 
basicity of the solution. The solution was left to cool and then vacuum filtered to give a white 
powder (89.7 mg, 0.07 mmol, 17 % yield, BiC51H55F3N9O11, Mr: 1235.38 g mol-1).  
m.p: 323-326 ℃ (lit19: 322-324 ℃). 
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IR: 1616 cm-1 (m, C=C stretching, conjugated alkene), 1610 cm-1 (m, O=C-O asymmetric 
stretching), 1358 cm-1 (m, O=C-O symmetric stretching), 1291 cm-1 (s, C-F stretching), 538 cm-1 
(m, Bi(III)-O stretching).  
 
Figure 64: numbered ciprofloxacin structure for the assignment of NMR peaks in 
[Bi(ciprofloxacin)3(H2O)]. 
1H NMR (400 MHz, DMSO-d6) δH 8.66 (s, C=CH42, 23,1H), 7.90 (d,3JH,F = 13.4 Hz, Ar-H36, 1H), 
7.54 (d, 4JH,F = 7.6 Hz, Ar-H26, 1H), 3.83 (tt, 3JH,H = 7.4, 4.0 Hz, H39, 2H), 3.32 (s, H31/35, 2H), 3.23 
(dd, 3JH,H = 6.1, 3.5 Hz, H32/34, 4H), 2.93 – 2.86 (m, H40/41, 2H), 1.35 – 1.13 (m, H40/41, 4H).  
13C NMR (101 MHz, DMSO-d6) δC 176.8 (s, C=O, C24), 166.0 (s, COO-, C22), 148.0 (s, C=C, C42), 
139.3 (s, C=C36), 106.2 (s, C=C37), 50.7 (s, C31/35), 45.4 (s, C32/34), 35.9 (s, C39), 7.6 (s, 
C40/41).  
19F NMR {1H}(376 MHz, DMSO-d6) δF -121.36 (dd, J = 13.7, 7.5 Hz, F28). 
CHN C: 48.69%, H: 5.64%, N: 9.85% (theoretical: C=49.56 %, H=4.49 %, N=10.20 %).  
Data consistent with literature values19 
5.2.3.4  zinc(II)- ciprofloxacin: Zn(ciprofloxacin)(OH)(H2O)2 ZnC34H38F2N6O8 (Mr: 762.0888 g mol-
1)Ciprofloxacin (C17H18FN3O3, 0.10 g, 0.3 mmol) sodium salt was added to a warmed solution of 
hydrochloric acid (1 mL, 0.1 M). A solution of anhydrous zinc(II) chloride (ZnCl2, 20 mg, 0.2 mmol) 
in deionised water (2 mL) was added to the ciprofloxacin solution. The new solution was refluxed 
for one hour and then cooled to room temperature. Methanol (1 mL) was added and left at 
room temperature for 24 hours. The resulting solution was filtered and washed with ethanol 
and then ether and left to dry, to give a white powder (89.8 mg, 0.1 mmol, 80 % yield).  
See figure 64 for atom labels  
m.p: 282- 284 ℃.  
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IR: 3410 cm-1 (s, O-H stretching, water), 1614 cm-1 (m, O=C-O asymmetric stretching), 1379 cm-1 
(m, O=C-O symmetric stretching), 1253 cm-1 (s, C-F stretching), 624 cm-1 (m, Zn(II)-O stretching).  
13C ssNMR: {1H}(5 kHz) δC  171(s, C=O, C24), 165(s, COO-, C22), 152(s, C27), 146(s, CH, C42), 143 
(s, CH, C36), 124(s, C25), 115(s, CH, C26), 110(s, C37), 50(s, CH2, C31/35), 47(m, CH2, C32/34), 
39(m, CH, C39), 12(m, CH2, C40/41). 
19F ssNMR: {1H}(10 kHz) δF  -131(s, F28). 
CHN: C: 47.16 %, H: 5.15 %, N: 9.54 % (theoretical: C=45.50 %, H=4.94 % and N=9.36 %). 
5.2.4 Dimer complex synthesise 
 
5.2.4.1 Ciprofloxacin methyl ester  
 
C18H21FN3O3 
Mr: 346.1561 g mol-1 
The reaction was carried out under the exclusion of air and moisture. A solution of ciprofloxacin 
(C17H18FN3O3,1.50 g, 4.5 mmol) in dry methanol (50 mL) was stirred for 30 minutes in an 
ice/water bath. Thionyl chloride (6.5 mL, 89.6 mmol) was added dropwise to the ciprofloxacin 
solution, causing an instant white to yellow colour change and resulting in a clear yellow 
solution. The resulting solution was refluxed for 24 hours and allowed to cool to room 
temperature before the solvent and residual thionyl chloride was removed. An aqueous 
potassium carbonate solution (50 mL, 5% w/v) was added to the residue and extracted with 
DCM (3 x 20 mL). The organic extract was washed with deionised water (2 x 10 mL). An aqueous 
potassium carbonate solution (50 mL, 5% w/v) was added to the resulting aqueous fractions and 
the combined fractions were re-extracted with DCM (3 x 20 mL) and washed with deionised 
water (2 x 10 mL). The collective organic fractions were dried over MgSO4 and the solvent was 
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removed via rotary evaporation to give a white powder. The resulting powder was recrystallised 
from hot MeCN to give a white powder (43-64, 1.01 g, 2.9 mmol, 65% yield).  
m.p: 226-228 ℃ (lit126 = 227 – 228 ℃).    
 
IR: 2951 cm-1 (w, C-H stretching, alkane), 1721 cm-1 (s, C=O stretching, ester), 1618 cm-1 (s, C-O 
stretching, ester), 1478 cm-1 (s, C-O stretching, ester),  1256 cm-1 (s, C-F stretching), 893 cm-1 (s, 
(C=C bending, alkene). 
1H NMR (400 MHz, Chloroform-d) δH 8.48 (s, H64, 1H), 7.94 (d, H48, 3JH,F = 13.4 Hz, 1H), 7.22 (d, 
4JH,F = 7.2 Hz, H58, 1H), 3.87 (s, H43, 3H), 3.42 (tt, 3JH,H = 7.3, 3.9 Hz, H61, 1H), 3.24 – 3.18 (m, 
H53/57, 4H), 3.08 (d,3JH,H = 5.1 Hz, H54/56, 4H), 2.34 (s, H55, 1H), 1.29 (t, 1J = 6.7 Hz, H62/63, 
2H), 1.12 (d, 1J = 4.6 Hz, H62/63, 2H).  
13C NMR (101 MHz, Chloroform-d) δC 173.3 (s, C=O, C46), 166.64 (s, C=O, C44), 153.6 (d, 1JC,F = 
250 Hz, C49), 148.5 (s, C64), 145.2 (d, 2JC,F = 11.1 Hz, C58), 138.2 (s, C45), 123.2 (d, 3JC,F = 6.1 Hz, 
C47), 113.4 (d, 3JC,F = 23.1 Hz, C48), 110.2 (s, C59), 104.9 (d, 3JC,F = 3.0 Hz, C58),  52.2 (s, C53/57), 
46.1 (s, C54/56), 34.7 (s, C61), 8.3 (s, C62/63).  
19F NMR {1H}(376 MHz, Chloroform-d) δF -123.42 (s, F50).  
MS (ESI +, CH3OH) found m/z 346.1561 (calc. for C18H21FN3O3= m/z 346.1561, 0.2 ppm error). 
CHN C: 61.78%, H: 5.75 %, N: 11.9 % (theoretical: C=62.61 %, H=5.84 %, N=12.17 %). 


















Mr: 946.95 g mol-1 
Figure 65: structure of 2-({2-[(carboxymethyl)(2-{4-[1-cyclopropyl-6-fluoro-3-
(methoxycarbonyl)-4-oxo-1,4- dihydroquinolin-7-yl]piperazin-1-yl}-2-oxoethyl)amino]ethyl}(2-
{4-[1-cyclopropyl-6-fluoro-3- (methoxycarbonyl)-4-oxo-1,4-dihydroquinolin-7-yl]piperazin-1-
yl}-2-oxoethyl)amino)acetic acid, referred to as [EDTA(ciprofloxacin methyl ester)2]. 
The reaction was carried out under the exclusion of air and moisture. Methyl-protected 
ciprofloxacin (C18H20FN3O3, 335 mg, 0.97 mmol) and EDTA dianhydride (C10H12N2O6, 125 mg, 0.49 
mmol) were added to dry DMF (5 mL) and stirred under nitrogen at 70 ℃ for 18 hours. The 
solvent was removed, and the resulting precipitate was first triturated with methanol (1.25 mL) 
and acetone (12.5 mL), then triturated a further four times with acetone, the final time the 
solvent was removed via rotary evaporation. A dry off-white powder was produced (310 mg, 
0.33 mmol, 68 % yield). The product was only found to be soluble in aqueous sodium hydroxide, 
which hydrolysed at the terminal methyl ester groups, forming the [EDTA(ciprofloxacin)2] 
compound, characterisation of which can be found in section 5.2.4.3.  
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5.2.4.3 EDTA-ciprofloxacin dimer [EDTA(ciprofloxacin)2]  
 
C44H44F2N8O12Na4.7H2O 
Mr: 1132.34 g mol-1 
Figure 66: numbering scheme used for the NMR assignment of of 7-[4-(2-{[2-({2-[4-(3-carboxy-
1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl]-2-
oxoethyl}(carboxymethyl)amino)ethyl(carboxymethyl)amino}acetyl)piperazin-1-yl]-1- 
cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, formed in an NMR tube with 
DMSO-d6 and sodium hydroxide, referred to as [EDTA(ciprofloxacin)2]. Spectra described below. 
 
 [EDTA(ciprofloxacin methyl ester)2] (C46H52F2N8O12, 194 mg, 0.2 mmol) was stirred in a sodium 
hydroxide solution (5 mL, 0.25 M) for 18 hours, resulting in a clear, colourless solution. 
Hydrochloric acid (1 M) was added dropwise to the solution, until indicator paper showed the 
solution had been neutralised. A precipitate formed, which was vacuum filtered and washed 
with deionised water to give a yellow precipitate (65-86, 148 mg, 0.1 mmol, 50% yield).  
m.p: 195-196 ℃.  
IR: 3017 cm-1 (w, C-H stretching, alkene), 2854 cm-1 (w, C-H stretching, alkane), 1723 cm-1 (w, C-
H bending, aromatic), 1626 cm-1 (m, O=C-O asymmetric stretching), 1453 cm-1 (m, C-H bending, 
alkane), 1335 cm-1 (m, O=C-O symmetric stretching),1245 cm-1 (s, C-F stretching), 1025 cm-1 (m, 
C-N stretching, amine), 885 cm-1 (s, C=C bending, alkene). 
1H NMR (400 MHz, D2O/ NaOD) δH 8.35 (s, C=C-H77, 1H), 7.59 (dd, 3JH,F = 13.3, 2.6 Hz, Ar-H69, 
1H), 7.37 – 7.19 (m, Ar-H72, 1H), 3.57 (d, 3JH,H = 23.1 Hz, piperazine H78/79, 4H), 3.40 (m, 
cyclopropyl H74,1H), 3.15 (d, 3JH,H = 2.9 Hz, piperazine H80/81, 4H), 2.92 (s, H86, 4H), 1.17 (m, 
1JH,H = 6.0 Hz, cyclopropyl H75/76, 2H), 0.91 (m, cyclopropyl H75/76, 2H).  
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13C NMR (101 MHz, D2O) δC 175.07 (s, C67), 172.1 (s, C=O, C67), 171.4 (s, COOH, C65), 151.19 (s, 
C77), 143.2 (d, 2JC,F = 10.6 Hz, C71), 138.07 (s, C72), 121.76 (d, 3JC,F = 7.0 Hz, C68), 105.7 (s, C73), 
51.8 (s, C78/79), 34.6 (s, C80/81), 27.24 (s, C74), 7.3 (s, C75/76). 
19F NMR {1H}(400 MHz, DMSO-d6) δF -124.23 (s, CF).  
MS (ESI-, NaOH) found m/z 917.3258 (calc. for C44H47F2N8O12 = m/z 917.3287, 2.9 ppm error), 
m/z 939.3080 (C44H46F2N8NaO12= m/z 393.3106, 1.6 ppm error).  
CHN C: 46.88 %, H: 5.07 %, N: 9.52 % (theoretical: C=46.65 %, H=5.16 %, N=9.89 %.) 
5.2.4.4 DTPA-ciprofloxacin methyl ester dimer [DTPA(ciprofloxacin methyl ester)2] 
 
C50H59F2N9O14 
Mr: 1047.41 g mol-1 
The reaction was carried out under the exclusion of air and moisture. DTPA dianhydride 
(C14H19N3O8, 0.03 g, 0.1 mmol) was added to a solution of ciprofloxacin methyl-ester 
(C18H21FN3O3, 0.0600 g, 0.2 mmol) in dry DMSO (5 mL). The resulting solution was stirred under 
nitrogen for 18 hours at 70 ℃. Acetone (45 mL) was added to the reaction solution and sonicated 
then centrifuged before the solvent was removed, this was repeated five times. On the final 
addition of acetone, the solvent was removed via rotary evaporation, leaving an off-white 
precipitate (87-118, 16 mg, 0.05 mmol, 56 % yield).  
MS (ESI -, CH3OH) found m/z 1046.4034 (calc. for C50H58F2N9O14= m/z 1046.4077, 0.7 ppm error).  
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5.2.4.5 DTPA-ciprofloxacin dimer [EDTA(ciprofloxacin)2] 
 
C48H50F2N9O14Na5.2NaCl.3H2O 
Mr: 1246.80 g mol-1 
[EDTA(ciprofloxacin methyl ester)2] (C50H59F2N9O14, 16 mg, 0.05 mmol) was dissolved in sodium 
hydroxide (NaOH, 0.01 M, 10 mL, 0.09 mmol) and stirred for 24 hours at room temperature. 
After 24 hours hydrochloric acid (HCl, 0.1 M) was added dropwise until the basic solution was 
neutralised, determined with universal indicator paper. During the neuralisation a pale blue 
precipitate formed. The precipitate was isolated via rotary evaporation. The precipitate was 
triturated with acetone three times before being isolated via rotary evaporation, giving a yellow 
precipitate (119-149, 10 mg, 0.01 mmol, 22 % yield).  
m.p: 205-206 ℃.  
IR: 3381 cm-1 (m, N-H stretching, amine), 2982 cm-1 (m, C-H stretching, alkane),1659 cm-1 (m, 
C=C stretching, alkene), 1616 cm-1 (m, O=C-O asymmetric stretching), 1387 cm-1 (m, O=C-O 
symmetric stretching), 1273 cm-1 (s, C-F stretching). 
1H NMR (400 MHz, DMSO-d6 / NaOD) δH 7.81 – 7.69 (m, C=CH141, 1H), 3.72 (m, 3JH,H = 3.6 Hz, 
cyclopropyl H143, 1H), 3.65 (d, 3JH,H = 5.1 Hz, H132, 2H), 3.45 (dd, 3JH,H = 14.7, 6.8 Hz, piperazine 
H129/149, 4H), 2.94 (d, 3JH,H = 8.1 Hz, piperazine H128/148, 4H), 2.86 (s, H136, 2H), 2.10 (s, H134, 
2H), 1.27 (m, cyclopropyl H144/145, 2H), 1.10 (m, cyclopropyl H144/145, 2H).  
13C NMR (101 MHz, DMSO-d6 / NaOD) δC 173.2 (s, C121), 173.1 (s, C119), 166.8 (d, 1JC,F = 374.7 
Hz, C124), 143.6 (d, 2JC,F = 9.8 Hz, C126), 138.0 (s, C147), 109.4 (s, C146), 51.3 (s, C128/148), 34.8 
(s, C129/149), 32.2 (s, C143), 7.6 (s, C144/145).  
19F NMR {1H}(376 MHz, DMSO-d6) δF -124.31 – -124.64 (m, F125).  
MS   product was not soluble enough to get a spectrum  
CHN C: 44.64 %, H: 4.52 %, N: 9.23 % (theoretical: C = 44.3186 %, H = 4.3391 %, N = 9.6907 %.) 
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5.2.5 Crystallisation Methods  
 
Figure 67: diagrams of crystallisation methods described in this section. 
5.2.5.1 Solvent layering  
The solution containing the product was divided into aliquots and an equal volume of an anti-
solvent (which the product is not soluble in) was added to the aliquots (figure 67). As the original 
solvent evaporates off, the product ‘crashes out’ in the anti-solvent. 
 5.2.5.2 Vapour diffusion  
The solution containing the product was divided into aliquots in small vials. An equivalent 
volume of a volatile anti-solvent (which the product is not soluble in) was added to a larger vial 
(figure 67). The smaller vial with the product solution was placed inside the larger vial with the 
anti-solvent in. The large sample vial was then sealed, allowing the anti-solvent vapour to diffuse 









ATP  Adenosine triphosphate  
btc  Trimesic acid  
Cf-  Ciprofloxacin 
cfA  7-(4-(decanoyl)piperazin-1-yl)-ciprofloxacin  
cfH  Protonated ciprofloxacin  
CHN  Elemental analysis of carbon, hydrogen and nitrogen  
COSY  1H1H correlation spectrum 
CSD  Cambridge structural database  
cym  Cymene  
DMSO  Dimethyl sulfoxide 
DTPA  Diethylenetriamine pentaacetate 
EDTA  Ethylenediaminetetraacetic acid  
FTIR  Fourier transform infrared spectroscopy  
HPLC  High performance liquid chromatography  
IR  Infrared radiation  
m.p.  Melting point  
MIC  Minimum inhibitory concentration  
MS  Mass spectrometry  
NMR  Nuclear magnetic resonance  
nta  nitrilotricetato  
oba  2-(oxalyl-amino)-benzoic acid 
odpa  Octadecylphosphonic acid 
Ox  Oxalate  
phen  Phenethylamine  
PMQR  Plasmid mediated quinolone resistance 
scXRD  Single crystal X-ray diffraction  
ssNMR  Solid state nuclear magnetic resonance  




6. Appendices  
 
6.1 Ciprofloxacin sodium salt 
 













































































































6.3.2 X-ray crystal structure data and refinement  
Crystal data and structure 
refinement 
(1) (2) (3) 
Empirical formula C34H44.84Cl2.98F2FeN6O12.74 C17H19FN4O6 C51H58F3Fe2N9O24S3  
Formula weight 941.06 394.36 1445.94  
Temperature/K 110.00(10) 110.05(10) 110.00(10)  
Crystal system monoclinic triclinic triclinic  
Space group I2/a P-1 P-1  
a/Å 15.0765(4) 6.5649(3) 13.8361(5)  
b/Å 20.9070(5) 10.5826(5) 15.3995(4)  
c/Å 17.9328(5) 12.5989(6) 17.2045(8)  
α/° 90 73.023(4) 67.583(3)  
β/° 112.582(3) 87.216(3) 79.960(4)  
γ/° 90 85.734(4) 89.311(3)  
Volume/Å3 5219.1(3) 834.51(7) 3330.9(2)  
Z 4 2 2  
ρcalc g/cm3 1.198 1.569 1.442  
μ/mm1 4.263 1.092 5.157  
F(000) 1950.0 412.0 1492.0  
Crystal size/mm3 0.198 × 0.168 × 0.133 0.137× 0.089 
× 0.06 
0.152 × 0.084 × 
0.076  
Radiation Cu Kα (λ = 1.54184) CuKα (λ = 
1.54184) 
CuKα (λ = 1.54184)  
2Θ range for data collection/° 7.63 to 134.134 7.34 to 
134.156 
7.794 to 142.248  
Index ranges -18 ≤ h ≤ 11, -24 ≤ k ≤ 24, 
-21 ≤ l ≤ 21 
-7 ≤ h ≤ 7, -
11 ≤ k ≤ 12, -
15 ≤ l ≤ 15 
-16 ≤ h ≤ 14, -18 ≤ 
k ≤ 13, -20 ≤ l ≤ 20  
Reflections collected 9384 11424 23793  
Independent reflections 4648 [Rint = 0.0172, Rsigma 
= 0.0234] 




12608 [Rint = 
0.0319, Rsigma = 
0.0485]  
Data/restraints/parameters 4648/0/321 2983/0/344 12608/0/976  
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Goodness-of-fit on F2 1.065 1.055 1.028  
Final R indexes [I>=2σ (I)] R1 = 0.0468, wR2 = 
0.1442 
R1 = 0.0306, 
wR2 = 0.0854 
R1 = 0.0501, wR2 = 
0.1175  
Final R indexes [all data] R1 = 0.0494, wR2 = 
0.1477 
R1 = 0.0342, 
wR2 = 0.0888 
R1 = 0.0675, wR2 = 
0.1277  




























6.3.3 X-ray crystal structure bond lengths 
Atom  Atom Length/Å   Atom  Atom Length/Å 
C1 C2 1.489(3)   C11 N2 1.473(3) 
C1 O1 1.275(3)   C12 N3 1.485(3) 
C1 O2 1.246(3)   C13 C14 1.527(3) 
C2 C3 1.419(3)   C13 N3 1.488(3) 
C2 C10 1.378(3)   C14 N2 1.467(3) 
C3 C4 1.446(3)   C15 C16 1.497(3) 
C3 O3 1.279(3)   C15 C17 1.492(3) 
C4 C5 1.404(3)   C15 N1 1.457(3) 
C4 C9 1.404(3)   C16 C17 1.507(4) 
C5 C6 1.368(3)   Cl1  Fe2 2.293(3) 
C6 C7 1.421(3)   Fe2  O11 1.997(16) 
C6 F1 1.352(2)   Fe2  O1 1.997(16) 
C7 C8 1.396(3)   Fe2  O3 2.029(15) 
C7 N2 1.395(3)   Fe2  O31 2.029(15) 
C8 C9 1.400(3)   Fe2  O4 2.028(5) 
C9 N1 1.398(3)   Fe2  O41 2.028(5) 
C10  N1 1.341(3)   Cl3  Cl31 1.431(17) 






6.3.4 X-ray crystal structure bond angles 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
O1 C1 C2 119.20(19)   O1 Fe2 Cl1 96.65(8) 
O2 C1 C2 118.70(2)   O11 Fe2 Cl11 96.65(8) 
O2 C1 O1 122.10(2)   O11 Fe2 Cl1 94.27(8) 
C3 C2 C1 122.92(19)   O11 Fe2 Cl1 94.27(8) 
C10 C2 C1 117.86(19)   O1 Fe2 O11 166.31(9) 
C10 C2 C3 119.21(19)   O11 Fe2 O3 85.48(6) 
C2 C3 C4 116.74(19)   O11 Fe2 O31 84.99(6) 
O3 C3 C2 124.27(19)   O1 Fe2 O3 84.99(6) 
O3 C3 C4 118.99(19)   O1 Fe2 O31 85.48(6) 
C5 C4 C3 120.40(2)   O11 Fe2 O41 97.03(16) 
C9 C4 C3 120.97(19)   O11 Fe2 O4 92.04(15) 
C9 C4 C5 118.60(19)   O1 Fe2 O4 97.03(16) 
C6 C5 C4 119.50(2)   O1 Fe2 O41 92.04(15) 
C5 C6 C7 123.40(2)   O3 Fe2 Cl11 171.08(9) 
F1 C6 C5 117.60(2)   O31 Fe2 Cl1 171.08(9) 
F1 C6 C7 118.98(19)   O31 Fe2 Cl11 97.20(9) 
C8 C7 C6 116.34(19)   O3 Fe2 Cl1 97.20(9) 
N2 C7 C6 120.80(2)   O31 Fe2 O3 91.61(9) 
N2 C7 C8 122.70(2)   O4 Fe2 Cl11 85.50(2) 
C7 C8 C9 121.10(2)   O41 Fe2 Cl11 11.50(16) 
C8 C9 C4 120.92(19)   O4 Fe2 O3 85.78(17) 
N1 C9 C4 118.78(18)   O41 Fe2 O31 85.78(18) 
N1 C9 C8 120.29(19)   O41 Fe2 O3 176.20(16) 
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N1 C10 C2 123.96(19)   O4 Fe2 O31 176.20(16) 
N2 C11 C12 109.90(2)   O41 Fe2 O4 97.00(3) 
N3 C12 C11 109.50(2)   C9 N1 C15 120.13(17) 
N3 C13 C14 110.80(2)   C10 N1 C9 119.94(18) 
N2 C14 C13 111.10(2)   C10 N1 C15 119.78(18) 
C17 C15 C16 60.56(17)   C7 N2 C11 117.80(18) 
N1 C15 C16 118.20(2)   C7 N2 C14 115.94(19) 
N1 C15 C17 118.55(19)   C14 N2 C11 111.36(19) 
C15 C16 C17 59.57(16)   C12 N3 C13 110.77(19) 
C15 C17 C16 59.87(16)   C1 O1 Fe2 128.29(14) 





































6.4.2 X-ray crystal structure bond lengths 
Atom Atom Length/Å   Atom Atom Length/Å 
Fe1 O1 1.9620(19)   C4 C5 1.407(4) 
Fe1 O2 1.955(2)   C13 C12 1.392(5) 
Fe1 O6 2.021(2)   C5 C10 1.402(4) 
Fe1 O3 1.977(2)   N2 C45 1.397(4) 
Fe1 O4 2.050(2)   N2 C48 1.455(5) 
Fe1 O5 2.055(2)   N2 C51 1.460(5) 
Fe2 O12 1.968(2)   C6 C2 1.493(4) 
Fe2 O11 2.036(2)   C10 C11 1.353(4) 
Fe2 O15 2.050(2)   C30 C29 1.389(4) 
Fe2 O13 1.984(2)   C12 C11 1.427(4) 
Fe2 O14 1.967(2)   C3 C2 1.383(4) 
Fe2 O16 1.963(3)   C27 C28 1.350(4) 
S003 O3 1.514(2)   C24 C26 1.487(4) 
S003 O9 1.468(2)   C24 C25 1.500(4) 
S003 O10 1.457(3)   N3 C50 1.492(5) 
S003 O8 1.458(3)   N3 C49 1.497(6) 
S004 O13 1.492(2)   C28 C29 1.430(4) 
S004 O23 1.463(2)   N5A C29 1.437(6) 
S004 O22 1.460(3)   N5A C31A 1.466(7) 
S004 O24 1.477(2)   N5A C34A 1.458(7) 
S005 O16 1.514(4)   C38 C47 1.408(5) 
S005 O21A 1.304(17)   C38 C37 1.408(4) 
S005 O19A 1.461(6)   C38 C39 1.445(4) 
S005 O20A 1.457(8)   C46 C47 1.354(4) 
F3 C46 1.359(4)   C46 C45 1.411(5) 
F2 C28 1.353(4)   C37 C44 1.408(5) 
O1 C1 1.291(3)   C39 C35 1.417(5) 
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O12 C23 1.285(3)   C7 C9 1.501(5) 
O2 C6 1.290(4)   C7 C8 1.491(5) 
O11 C18 1.285(3)   C45 C44 1.385(5) 
O15 C39 1.279(4)   C26 C25 1.495(5) 
O7 C6 1.234(4)   C29 N5 1.313(12) 
F1 C11 1.358(4)   C35 C36 1.375(5) 
O14 C40 1.280(5)   C35 C40 1.497(5) 
O17 C23 1.236(4)   C48 C49 1.532(5) 
N4 C21 1.392(4)   C9 C8 1.495(6) 
N4 C20 1.339(4)   C51 C50 1.518(5) 
N4 C24 1.464(3)   C41 C43 1.487(7) 
N7 C4 1.395(4)   C41 C42 1.480(5) 
N7 C3 1.337(4)   C43 C42 1.471(8) 
N7 C7 1.459(4)   C31A C32A 1.519(8) 
N8 C12 1.377(4)   C31 C32 1.522(14) 
N8 C14 1.496(7)   C31 N5 1.474(15) 
N8 C17 1.462(7)   C32A N6 1.504(9) 
N8 C14A 1.451(10)   C14 C15 1.521(8) 
N8 C17A 1.376(9)   C17 C16 1.532(8) 
O16 S0 1.539(6)   C14A C15A 1.478(14) 
N1 C37 1.388(4)   C15 N9 1.485(8) 
N1 C36 1.354(5)   C16 N9 1.474(8) 
N1 C41 1.462(4)   C16A C17A 1.497(11) 
C18 C22 1.428(4)   C16A N9A 1.488(13) 
C18 C19 1.418(4)   C34A C33A 1.466(9) 
C1 C5 1.442(4)   N9A C15A 1.498(15) 
C1 C2 1.409(4)   N6 C33A 1.500(9) 
O18 C40 1.253(5)   N6A C33 1.448(15) 
C22 C21 1.411(4)   N6A C32 1.478(14) 
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C22 C27 1.412(4)   C33 C34 1.504(15) 
C21 C30 1.392(4)   C34 N5 1.459(16) 
C19 C20 1.380(4)   O19 S0 1.454(9) 
C19 C23 1.496(4)   O20 S0 1.505(11) 





6.4.3 X-ray crystal structure bond angles 
A B C D Angle/˚   A B C D Angle/˚ 
Fe1 O1 C1 C5 162.15(19)   C30 C29 N5 C34 23.3(13) 
Fe1 O1 C1 C2 -20.1(4)   C12 N8 C14 C15 -117.7(5) 
Fe1 O2 C6 O7 -171.9(2)   C12 N8 C17 C16 118.8(5) 
Fe1 O2 C6 C2 6.9(4)   C12 N8 C14A C15A -141.3(7) 
Fe2 O12 C23 O17 168.3(2)   C12 N8 C17A C16A 142.3(5) 
Fe2 O12 C23 C19 -12.4(4)   C3 N7 C4 C13 175.2(3) 
Fe2 O11 C18 C22 -148.4(2)   C3 N7 C4 C5 -3.4(4) 
Fe2 O11 C18 C19 32.3(4)   C3 N7 C7 C9 108.7(4) 
Fe2 O15 C39 C38 -145.5(2)   C3 N7 C7 C8 39.2(5) 
Fe2 O15 C39 C35 31.8(4)   C27 C22 C21 N4 179.7(3) 
Fe2 O14 C40 O18 160.1(3)   C27 C22 C21 C30 -1.1(4) 
Fe2 O14 C40 C35 -21.2(5)   C27 C28 C29 C30 0.2(6) 
Fe2 O16 S0 O19 78.1(13)   C27 C28 C29 N5A 168.4(4) 
Fe2 O16 S0 O20 -161.6(12)   C27 C28 C29 N5 -159.4(7) 
Fe2 O16 S0 O21 -47.0(14)   C24 N4 C21 C22 175.4(3) 
F3 C46 C47 C38 -175.7(3)   C24 N4 C21 C30 -3.7(4) 
F3 C46 C45 N2 1.2(5)   C24 N4 C20 C19 -176.8(3) 
F3 C46 C45 C44 176.0(3)   C2 C1 C5 C4 0.6(4) 
F2 C28 C29 C30 -175.9(3)   C2 C1 C5 C10 -179.5(3) 
F2 C28 C29 N5A -7.7(6)   C28 C29 N5 C31 37.1(13) 
F2 C28 C29 N5 24.5(8)   C28 C29 N5 C34 -177.9(8) 
O1 C1 C5 C4 178.5(3)   N5A C31A C32A N6 -60.0(6) 
O1 C1 C5 C10 -1.6(4)   N5A C34A C33A N6 57.6(7) 
O1 C1 C2 C6 0.3(5)   C38 C37 C44 C45 1.5(5) 
O1 C1 C2 C3 -179.2(3)   C38 C39 C35 C36 -5.7(5) 
O2 C6 C2 C1 6.8(4)   C38 C39 C35 C40 174.3(3) 
O2 C6 C2 C3 -173.8(3)   C46 C45 C44 C37 -0.7(5) 
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O11 C18 C22 C21 -178.0(3)   C47 C38 C37 N1 179.2(3) 
O11 C18 C22 C27 2.3(4)   C47 C38 C37 C44 -1.1(5) 
O11 C18 C19 C20 176.6(3)   C47 C38 C39 O15 4.8(5) 
O11 C18 C19 C23 -1.1(5)   C47 C38 C39 C35 -172.7(3) 
O15 C39 C35 C36 177.0(3)   C47 C46 C45 N2 -175.4(3) 
O15 C39 C35 C40 -3.0(5)   C47 C46 C45 C44 -0.5(5) 
O7 C6 C2 C1 -174.3(3)   C37 N1 C36 C35 4.0(5) 
O7 C6 C2 C3 5.1(4)   C37 N1 C41 C43 -66.4(5) 
O23 S004 O13 Fe2 -21.3(3)   C37 N1 C41 C42 -134.9(5) 
N4 C21 C30 C29 -179.8(3)   C37 C38 C47 C46 -0.1(5) 
N4 C24 C26 C25 -107.9(3)   C37 C38 C39 O15 179.7(3) 
N4 C24 C25 C26 109.5(3)   C37 C38 C39 C35 2.3(5) 
O9 S003 O3 Fe1 36.7(2)   C39 C38 C47 C46 175.1(3) 
N7 C4 C13 C12 178.7(3)   C39 C38 C37 N1 4.2(5) 
N7 C4 C5 C1 1.8(4)   C39 C38 C37 C44 -176.1(3) 
N7 C4 C5 C10 -178.1(3)   C39 C35 C36 N1 2.8(6) 
N7 C3 C2 C1 -0.3(5)   C39 C35 C40 O14 -4.5(5) 
N7 C3 C2 C6 -179.8(3)   C39 C35 C40 O18 174.2(4) 
N7 C7 C9 C8 -110.1(3)   O19A S005 O16 Fe2 109.3(8) 
N7 C7 C8 C9 106.9(4)   C7 N7 C4 C13 -4.0(4) 
O10 S003 O3 Fe1 157.56(19)   C7 N7 C4 C5 177.4(3) 
O8 S003 O3 Fe1 -82.2(2)   C7 N7 C3 C2 -178.1(3) 
O22 S004 O13 Fe2 101.0(2)   C45 N2 C48 C49 -155.5(4) 
N8 C12 C11 F1 1.7(5)   C45 N2 C51 C50 152.7(3) 
N8 C12 C11 C10 -177.2(3)   C45 C46 C47 C38 0.9(5) 
N8 C14 C15 N9 -59.6(6)   C29 N5A C31A C32A -86.1(6) 
N8 C17 C16 N9 59.3(7)   C29 N5A C34A C33A 86.6(6) 
N8 C14A C15A N9A -50.6(11)   C36 N1 C37 C38 -7.3(5) 
O24 S004 O13 Fe2 -139.0(2)   C36 N1 C37 C44 173.0(3) 
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O21A S005 O16 Fe2 -7.4(13)   C36 N1 C41 C43 117.7(4) 
N1 C37 C44 C45 -178.8(3)   C36 N1 C41 C42 49.3(6) 
N1 C41 C43 C42 -106.7(4)   C36 C35 C40 O14 175.5(3) 
N1 C41 C42 C43 108.9(5)   C36 C35 C40 O18 -5.8(6) 
C18 C22 C21 N4 0.0(4)   C40 C35 C36 N1 -177.1(3) 
C18 C22 C21 C30 179.2(3)   O20A S005 O16 Fe2 -130.5(8) 
C18 C22 C27 C28 -179.5(3)   C48 N2 C45 C46 163.9(3) 
C18 C19 C20 N4 2.8(5)   C48 N2 C45 C44 -10.6(6) 
C18 C19 C23 O12 -10.8(5)   C48 N2 C51 C50 -63.8(4) 
C18 C19 C23 O17 168.6(3)   C51 N2 C45 C46 -55.7(5) 
C1 C5 C10 C11 179.0(3)   C51 N2 C45 C44 129.8(4) 
C22 C18 C19 C20 -2.7(4)   C51 N2 C48 C49 61.3(4) 
C22 C18 C19 C23 179.6(3)   C50 N3 C49 C48 54.2(5) 
C22 C21 C30 C29 1.0(5)   C41 N1 C37 C38 176.9(3) 
C22 C27 C28 F2 175.7(3)   C41 N1 C37 C44 -2.8(5) 
C22 C27 C28 C29 -0.4(5)   C41 N1 C36 C35 179.9(4) 
C21 N4 C20 C19 -1.4(5)   C49 N3 C50 C51 -55.0(5) 
C21 N4 C24 C26 146.2(3)   C31A N5A C29 C30 -1.3(7) 
C21 N4 C24 C25 76.3(4)   C31A N5A C29 C28 -168.7(4) 
C21 C22 C27 C28 0.8(5)   C31A N5A C34A C33A -58.8(6) 
C21 C30 C29 C28 -0.5(5)   C31A C32A N6 C33A 59.2(7) 
C21 C30 C29 N5A -168.5(4)   C32A N6 C33A C34A -58.6(7) 
C21 C30 C29 N5 159.5(7)   C14 N8 C12 C13 17.4(6) 
C19 C18 C22 C21 1.4(4)   C14 N8 C12 C11 -163.3(4) 
C19 C18 C22 C27 -178.3(3)   C14 N8 C17 C16 -60.9(6) 
C4 N7 C3 C2 2.8(4)   C14 C15 N9 C16 57.5(7) 
C4 N7 C7 C9 -72.2(4)   C17 N8 C12 C13 -162.3(4) 
C4 N7 C7 C8 -141.7(3)   C17 N8 C12 C11 17.1(6) 
C4 C13 C12 N8 179.5(3)   C17 N8 C14 C15 62.1(6) 
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C4 C13 C12 C11 0.1(4)   C17 C16 N9 C15 -57.4(8) 
C4 C5 C10 C11 -1.1(4)   C14A N8 C12 C13 -17.1(7) 
C20 N4 C21 C22 -0.1(4)   C14A N8 C12 C11 162.3(6) 
C20 N4 C21 C30 -179.2(3)   C14A N8 C17A C16A -55.2(9) 
C20 N4 C24 C26 -38.4(4)   C16A N9A C15A C14A 51.0(11) 
C20 N4 C24 C25 -108.2(3)   C17A N8 C12 C13 145.2(6) 
C20 C19 C23 O12 171.5(3)   C17A N8 C12 C11 -35.4(7) 
C20 C19 C23 O17 -9.2(5)   C17A N8 C14A C15A 55.2(10) 
C13 C4 C5 C1 -176.8(3)   C17A C16A N9A C15A -51.6(10) 
C13 C4 C5 C10 3.3(4)   C34A N5A C29 C30 -143.8(5) 
C13 C12 C11 F1 -178.9(3)   C34A N5A C29 C28 48.8(7) 
C13 C12 C11 C10 2.2(5)   C34A N5A C31A C32A 60.0(6) 
C5 C1 C2 C6 178.1(3)   N9A C16A C17A N8 52.6(9) 
C5 C1 C2 C3 -1.3(4)   N6A C33 C34 N5 55.9(13) 
C5 C4 C13 C12 -2.8(4)   C33 N6A C32 C31 52.9(13) 
C5 C10 C11 F1 179.4(3)   C33 C34 N5 C29 153.8(10) 
C5 C10 C11 C12 -1.7(5)   C33 C34 N5 C31 -57.3(14) 
N2 C45 C44 C37 173.9(3)   C32 C31 N5 C29 -157.4(10) 
N2 C48 C49 N3 -56.0(5)   C32 C31 N5 C34 56.5(12) 
N2 C51 C50 N3 59.1(4)   C32 N6A C33 C34 -54.4(13) 
C23 C19 C20 N4 -179.3(3)   N5 C31 C32 N6A -53.1(13) 

















































































































































































































6.9 DTPA-ciprofloxacin methyl ester dimer  
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